


## REVIEW ARTICLE

# Artificial intelligence for dementia prevention

Danielle Newby<sup>1</sup>  | Vasiliki Orgeta<sup>2</sup> | Charles R. Marshall<sup>3,4</sup> | Ilianna Lourida<sup>5,6</sup> | Christopher P. Albertyn<sup>7</sup> | Stefano Tamburin<sup>8</sup> | Vanessa Raymont<sup>1</sup> | Michele Veldsman<sup>9,10</sup> | Ivan Koychev<sup>1</sup> | Sarah Bauermeister<sup>1</sup> | David Weisman<sup>11</sup> | Isabelle F. Foote<sup>3,12</sup> | Magda Bucholc<sup>13</sup> | Anja K. Leist<sup>14</sup> | Eugene Y. H. Tang<sup>5</sup> | Xin You Tai<sup>15,16</sup> | The Deep Dementia Phenotyping (DEMON) Network | David J. Llewellyn<sup>6,17</sup> | Janice M. Ranson<sup>6</sup>

<sup>1</sup>Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK

<sup>2</sup>Division of Psychiatry, University College London, London, UK

<sup>3</sup>Preventive Neurology Unit, Wolfson Institute of Population Health, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK

<sup>4</sup>Department of Neurology, Royal London Hospital, London, UK

<sup>5</sup>Population Health Sciences Institute, Newcastle University, Newcastle, UK

<sup>6</sup>University of Exeter Medical School, Exeter, UK

<sup>7</sup>Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK

<sup>8</sup>Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy

<sup>9</sup>Wellcome Centre for Integrative Neuroimaging, University of Oxford, Oxford, UK

<sup>10</sup>Department of Experimental Psychology, University of Oxford, Oxford, UK

<sup>11</sup>Abington Neurological Associates, Abington, Pennsylvania, USA

<sup>12</sup>Institute for Behavioral Genetics, University of Colorado Boulder, Boulder, Colorado, USA

<sup>13</sup>Cognitive Analytics Research Lab, School of Computing, Engineering & Intelligent Systems, Ulster University, Derry, UK

<sup>14</sup>Department of Social Sciences, Institute for Research on Socio-Economic Inequality (IRSEI), University of Luxembourg, Esch-sur-Alzette, Luxembourg

<sup>15</sup>Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK

<sup>16</sup>Division of Clinical Neurology, John Radcliffe Hospital, Oxford University Hospitals Trust, Oxford, UK

<sup>17</sup>The Alan Turing Institute, London, UK

### Correspondence

Danielle Newby, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences (NDORMS), Centre for Statistics in Medicine, University of Oxford, Windmill Road, Oxford OX3 7LD, UK.  
Email: [danielle.newby@ndorms.ox.ac.uk](mailto:danielle.newby@ndorms.ox.ac.uk)

David J. Llewellyn and Janice M. Ranson are joint senior authors.

### Funding information

Alzheimer's Research UK and the Alan Turing Institute/Engineering and Physical Sciences

### Abstract

**INTRODUCTION:** A wide range of modifiable risk factors for dementia have been identified. Considerable debate remains about these risk factors, possible interactions between them or with genetic risk, and causality, and how they can help in clinical trial recruitment and drug development. Artificial intelligence (AI) and machine learning (ML) may refine understanding.

**METHODS:** ML approaches are being developed in dementia prevention. We discuss exemplar uses and evaluate the current applications and limitations in the dementia prevention field.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

Research Council, Grant/Award Number: EP/N510129/1; Medical Research Council, Grant/Award Number: MR/X005674/1; National Institute on Aging/National Institutes of Health, Grant/Award Number: RF1AG055654; European Research Council, Grant/Award Number: 803239; George Henry Woolfe Legacy Fund and the National Institute on Aging, Grant/Award Number: RF1AG073593; Alzheimer's Research UK and Economic and Social Research Council, Grant/Award Number: ES/W010240/1; Barts Charity; Dr George Moore Endowment for Data Science at Ulster University; National Institute for Health Research; Dementias Platform UK (DPUK). The Medical Research Council supports DPUK, Grant/Award Number: MR/T0333771; Alzheimer's Research UK; EU (SEUPB) INTERREG, Grant/Award Numbers: ERDF/SEUPB, HSC R&D, COM/5750/23

**RESULTS:** Risk-profiling tools may help identify high-risk populations for clinical trials; however, their performance needs improvement. New risk-profiling and trial-recruitment tools underpinned by ML models may be effective in reducing costs and improving future trials. ML can inform drug-repurposing efforts and prioritization of disease-modifying therapeutics.

**DISCUSSION:** ML is not yet widely used but has considerable potential to enhance precision in dementia prevention.

#### KEYWORDS

artificial intelligence, dementia, machine learning, prevention, risk prediction

#### Highlights

- Artificial intelligence (AI) is not widely used in the dementia prevention field.
- Risk-profiling tools are not used in clinical practice.
- Causal insights are needed to understand risk factors over the lifespan.
- AI will help personalize risk-management tools for dementia prevention.
- AI could target specific patient groups that will benefit most for clinical trials.

## 1 | INTRODUCTION TO DEMENTIA PREVENTION, ARTIFICIAL INTELLIGENCE, AND MACHINE LEARNING

The incidence of dementia has been reported to be decreasing in some high-income countries.<sup>1,2</sup> However, the prevalence of dementia worldwide is predicted to triple over the next 30 years due to increases in life expectancy, particularly in low- and middle-income countries.<sup>3</sup> It is now recognized that pathological changes begin years before the onset of clinical symptoms of Alzheimer's disease (AD) and other dementia subtypes.<sup>4,5</sup> This creates a window of opportunity for early identification and development of targeted interventions and treatments that could ultimately prevent subsequent dementia. Estimates show that delaying AD onset by 5 years would reduce prevalence by 40%, which would have a huge public health impact.<sup>6</sup> In the absence of an effective cure, the identification of new strategies to prevent dementia cases is of critical importance. Thus dementia research has focused increasingly on the treatment of preclinical stages and the identification of modifiable risk factors.<sup>7</sup>

### 1.1 | Dementia prevention research

Decades of primary prevention research have included the assessment and identification of biological, behavioral, environmental, and social factors that may increase or decrease the likelihood of developing dementia. Findings from epidemiological studies provide a growing list of modifiable risk and protective factors across the life course that can be targeted for prevention.<sup>8</sup> Several interventional studies have tested the efficacy of prevention strategies in cognitively healthy

individuals at risk of dementia (primary prevention) or to prevent further cognitive decline or progression to dementia in people with mild cognitive impairment (MCI) or other early symptoms (secondary prevention). Dementia prevention clinical trials targeting single or multiple risk factors have evaluated a range of pharmacological (cholinesterase inhibitors) and non-pharmacological interventions (e.g., exercise programs, cognitive training, multidomain<sup>9</sup>). However, evidence that the treatment of these risk factors reduces the risk or progression of dementia remains weak.<sup>10–12</sup> Factors hindering progress in this area may include the difficulty in identifying the age and characteristics of the ideal target population, a lack of understanding of the causal pathways to be targeted, and the limitations of traditional statistical methods in analyzing high-dimensional multimodal data (e.g., imaging, biomarker, genetics, and medical records) and non-linear relationships between variables. This is particularly important in dementia prevention research, where hundreds, or even thousands, of genetic and non-genetic features may predict disease risk and progression,<sup>13</sup> and most of the proposed risk factors do not have a linear relationship with dementia risk throughout life.<sup>8</sup>

### 1.2 | Artificial intelligence and machine learning

Artificial intelligence (AI) refers to the broader field of computer science that focuses on creating machines or systems capable of performing tasks that would typically require human intelligence. Machine learning (ML) is a subset of AI that focuses on designing algorithms and models that enable computers to learn from and make predictions or decisions based on data without being explicitly programmed. The application of methodologies incorporating

AI and ML is gaining momentum in dementia prevention research (Figure 1).

In this review, we focus mainly on the application of ML methods in dementia prevention research, since this area of AI holds promise for advancing the field. ML can be broadly split into unsupervised, supervised, and semi-supervised methods. Unsupervised methods do not distinguish between dependent and independent variables (i.e., there is not a specified dementia-related outcome being predicted); rather, their goal is to discover patterns and associations between the variables (i.e., risk factor and dementia) to potentially define possible groups and clusters hidden in the data.<sup>14,15</sup> Unsupervised methods are applied under the assumption that similar outcomes (with similar variables) will be grouped together and reveal meaningful patterns not seen in the raw data.

Clustering methods such as multi-layer clustering, k-means clustering, hierarchical clustering, or Gaussian mixture models (GMMs) are unsupervised methods that have been applied in dementia prevention research, for example, to identify subgroups of individuals with MCI with markedly different prognostic cognitive trajectories.<sup>16</sup> The results from such studies can be used to identify subgroups of individuals that are at high risk of dementia to better understand different disease trajectories and tailor interventions or prevention strategies accordingly.<sup>17</sup> Unsupervised anomaly detection algorithms, including one-class support vector machines (SVMs), autoencoders (AEs), or isolation forests, have been utilized to identify unusual or atypical patterns in data.<sup>18,19</sup> In the context of dementia prevention, these methods could help detect outliers or abnormal biomarker patterns that may be indicative of underlying pathology or increased risk.<sup>18</sup> Other unsupervised methods include unsupervised latent variable models, such as latent Dirichlet allocation (LDA) or GMMs, which have been employed to identify latent structures or hidden variables in data, which can reveal hidden patterns or subgroup data sets that may be relevant for understanding dementia risk factors or disease progression.<sup>20,21</sup>


With supervised methods the dependent variable is known (i.e., dementia is specified to be the outcome), and it is this information plus the input from the independent variables (i.e., the risk factors) that guide the supervised ML method to predict the dependent variable.<sup>22</sup> These methods can be further split into regression or classification methods, where the dependent variable to be predicted is either numerical (continuous) or categorical.<sup>23</sup> Supervised ML methods such as logistic regression, random forest, SVMs, gradient boosting, deep learning, and decision trees can be utilized for clinical risk prediction<sup>24</sup>—for example, where dementia diagnostic status is known in combination with features such as demographics, imaging, biomarkers, genetics, comorbidities, symptoms, medication use, and other health indicators are used to build models useful for primary and secondary prevention.<sup>13,25–27</sup> Supervised methods have also been developed to classify biomarker data associated with dementia,<sup>28</sup> and these models can also be trained on neuroimaging data such as magnetic resonance imaging (MRI) or positron emission tomography (PET) scans to classify brain images as healthy or indicative of dementia-related abnormalities.<sup>29</sup> Similarly, classification models

## RESEARCH IN CONTEXT

1. **Systematic review:** The authors reviewed the literature on dementia prevention and describe the state of the science related to identification of modifiable risk factors, risk-prediction modeling, interventions, and drug repurposing. Major challenges to progress the dementia prevention field, with examples, and opportunities for artificial intelligence (AI) and machine learning (ML) applications to enhance prevention efforts are highlighted.
2. **Interpretation:** Although not yet widely used, AI and ML have considerable potential to enhance precision in dementia prevention. The flexibility and scalability of ML methods can facilitate the use of multimodal data to: (i) enhance understanding of potential interactions and causal status of risk factors, (ii) improve selection of important variables and performance of risk profiling, which in turn can: (a) assist clinical trial recruitment, reduce costs, and increase efficiency of trials, and (b) identify drug-repurposing candidates to accelerate discovery of disease-modifying treatments.
3. **Future directions:** Multidisciplinary collaboration is required to harness the potential of ML, maximize utilization of available resources and data access, and enhance traditional approaches to advance dementia prevention research.

can be developed using genetic markers or biomarkers obtained from cerebrospinal fluid to distinguish between individuals with or without dementia-related pathology.<sup>30</sup> Supervised methods can also be used to predict cognitive decline in individuals using longitudinal data. These models learn patterns in the data and can predict the future cognitive decline trajectory of individuals based on their baseline assessments and other risk factors.<sup>31</sup>

Finally, semi-supervised methods fall in-between supervised and unsupervised ML and use both labeled (e.g., information on dementia/MCI diagnosis) and unlabeled data.<sup>32</sup> Semi-supervised methods such as active learning<sup>33</sup> use a labeled data set to train a model, which is then used to select the most informative or uncertain samples from the unlabeled data set. These selected samples are then labeled manually by experts, and the model is retrained using the newly labeled data.<sup>34</sup> Active learning could be applied to various tasks in dementia prevention, such as identifying relevant risk factors or biomarkers, or targeted samples for clinical trials recruitment. Other methods include self-training where a model is initially trained on a small, labeled data set.<sup>35</sup> The model is then used to make predictions on the unlabeled data, and the most confident predictions are added to the labeled data set. This process is repeated iteratively, gradually expanding the labeled data set and improving the model's performance.<sup>33</sup> Self-training can be applied to tasks such as dementia-risk prediction, where a limited



**FIGURE 1** Growth in citations related to ML/AI in dementia prevention (1990–2022). Source: PubMed citations using the search term (Alzheimer\*[Title/Abstract] OR dement\*[Title/Abstract]) AND (Prevent\*[Title/Abstract] OR risk factor\*[Title/Abstract] OR determinant\*[Title/Abstract]) AND (AI[Title/Abstract] OR artificial intelligence[Title/Abstract] OR machine learning[Title/Abstract]).

number of labeled instances are available, but a large amount of unlabeled data exists. Finally, co-training is a semi-supervised technique that utilizes multiple views or feature sets of the data to improve the model's performance.<sup>36</sup> The model is trained on different sets of features or representations, each with its own labeled and unlabeled data. The model is then iteratively trained on each view and shares information between the views during training.<sup>36</sup> Co-training could be applied in dementia prevention by utilizing multiple modalities, such as genetic data, neuroimaging, and cognitive assessments, to improve the accuracy and robustness of predictive models. Semi-supervised methods use information from unlabeled data to improve the performance of models trained on labeled data.<sup>37,38</sup> A more in-depth description of ML methodologies and applications to the broader dementia field can be found in the methods optimization paper also included in this special issue.<sup>39</sup>

Traditional statistical approaches rely on using domain knowledge to create and fit mathematical models to represent the relationships between variables and provide a quantitative measure of confidence that describe associations.<sup>40–43</sup> In contrast, ML techniques do not make a priori assumptions about the distribution from which the modeling sample is drawn, and hence they can be effective even in the presence of complex non-linear relationships and when the data are collected without a controlled experimental design.<sup>44</sup> ML models

are more flexible and scalable compared with conventional statistical approaches, as they can explore the structure of high-dimensional multimodal data, detect patterns, and generate insights with minimal human intervention.<sup>45</sup> In this review, we provide a critical summary of the current state of the science, challenges, implications, and major opportunities for the application of ML to dementia prevention.

This review is one of a series of eight articles in a *Special Issue* on “Artificial Intelligence for Alzheimer's Disease and Related Dementias” published in *Alzheimer's & Dementia*. Together, this series provides a comprehensive overview of current applications of AI and ML to dementia, and future opportunities for innovation to accelerate research. Each review focuses on a different area of dementia research, including experimental models,<sup>46</sup> drug discovery and trials optimization,<sup>47</sup> genetics and omics,<sup>48</sup> biomarkers,<sup>49</sup> imaging,<sup>50</sup> prevention (this article), applied models and digital health,<sup>51</sup> and methods optimization.<sup>39</sup>

## 2 | USE OF ML TO UNDERSTAND MODIFIABLE RISK FACTORS FOR DEMENTIA PREVENTION

In this section we describe the current state of the science relating to the identification of risk factors for dementia and risk-prediction modeling. We then describe the major challenges that are hindering

progress and provide examples of ML applications to these problems. Finally, we discuss the opportunities of how ML methods could enhance and improve our understanding of risk factors by using different data types (multimodal data) and application of ML approaches from other disciplines.


## 2.1 | State of the science

### 2.1.1 | Identification of risk factors

Several lifestyle, psychosocial, and cardiometabolic risk factors play an important role in the development of dementia.<sup>52</sup> The Lancet Commission on Dementia Prevention, Intervention, and Care, first published in 2017, proposed a life course perspective to better understand how, and at which time point over the course of the human lifespan, nine potentially modifiable risk factors increase dementia risk. Fewer years of education during early life were found to increase risk, whereas chronic hypertension, obesity, and age-related hearing loss were considered to increase risk during mid-life. The remaining five factors (current smoking, depression, physical inactivity, social isolation, and type 2 diabetes) were shown to exert their effect in later life.<sup>53</sup> In the Lancet Commission's updated 2020 report, three new risk factors were added, two mid-life risk factors (alcohol consumption and traumatic brain injury) and one late-life risk factor (air pollution).<sup>8</sup>

Several additional systematic reviews<sup>54–58</sup> have been conducted within the last 10 years that aimed to comprehensively summarize the emerging evidence relating to dementia risk factors (Figure 2). The main risk factors highlighted by these reviews include those covered by the Lancet Commission as well as the dementia prevention guidelines from The World Health Organization (WHO). Evidence for other risk factors such as hyperlipidemia, coronary heart disease, renal dysfunction, poor diet, and cognitive inactivity were less consistent across reviews. More recent systematic reviews, which focus upon individual risk factors, also suggest the importance of additional risk factors, such as stroke<sup>59</sup> and delirium,<sup>60</sup> and it is likely that the number of “established” risk factors will grow as this body of evidence consolidates.

However, when considering the relationship between a proposed risk or protective factor with dementia, it is vital to consider a lifespan perspective, owing to the changing importance of potentially modifiable risk factors across the life course and the fact that dementia pathology is believed to begin up decades before it is detectable by current diagnostic methods (known as the prodromal phase).<sup>61–63</sup> For example, hypertension and obesity are both associated with increased future dementia risk during mid-life, but weight and blood pressure have been shown to decrease in later life in those with or developing dementia, indicating that in later life, changes in these risk factors are consequences of disease progression.<sup>64,65</sup> ML methods that consider the changing importance of risk factors using longitudinal data could be used to understand different disease trajectories and disease heterogeneity<sup>66</sup>



**FIGURE 2** Modifiable risk factors for dementia identified in prior systematic reviews and guidelines. Visualization of risk factors identified in (A) five prior systematic reviews and (B) the recent WHO guidelines (2019) and Lancet Commission (2020). Risk factors (circles) were divided into health risk, lifestyle, and environmental categories. The number of reviews that identified each risk factor is reflected by the relative size of each circle (shaded indicates comparatively stronger evidence, \* denotes a protective factor, whereas “E” and “M” represent early and mid-life risk factors, respectively. Anticoag, anticoagulant; BDZ, benzodiazepines; Cerebral SVD, cerebral small vessel disease; post-op delirium, post-operative delirium.

### 2.1.2 | Risk-prediction modeling

The purpose of risk-prediction models is to identify individuals who are at greatest risk of developing a disease to inform appropriate risk-reduction interventions. Numerous risk-prediction models for dementia have been developed, some of which have been externally



validated.<sup>67</sup> However, further work is required to assess their generalizability, cost-effectiveness, and predictive value before they can be recommended for use in clinical practice.<sup>68</sup> These models tend to use a combination of demographic, cognitive, health, lifestyle, and genetic factors to estimate an individual's risk of developing dementia using straightforward regression-based approaches. The Cardiovascular Risk Factors, Ageing and Dementia (CAIDE) model is one example, which uses age, education, and sex alongside the mid-life risk factors of body mass index, blood pressure, cholesterol, smoking history, and physical activity. The CAIDE was developed using logistic regression to predict dementia risk in 20 years with moderate levels of accuracy (area under the curve [AUC] 0.77; 95% confidence interval [CI] 0.71–0.83).<sup>69</sup> A recent study using a variety of different ML algorithms (logistic regression, SVMs, random forest, and gradient-boosted trees) was used to predict 2-year dementia risk and had superior accuracy compared to common dementia risk models including the CAIDE.<sup>13</sup> However, due to the long prodromal phase of dementia, the value of a prediction model that is optimized for prediction only 2 years prior to diagnosis is unlikely to be of primary preventative value, since high levels of neurodegeneration will already have occurred,<sup>61,62</sup> but it could help clinicians to identify patients who might be in the earlier stages of disease. The optimal period for dementia risk prediction will, therefore, require different risk-prediction tools targeting different stages of pathology and dementia progression. For example, for primary prevention, long-term risk profiling is useful because risk factors can potentially be modified,<sup>70</sup> whereas for secondary prevention, shorter-term risk profiling is more appropriate to identify those at higher risk of disease progression.<sup>13</sup>

A systematic review highlighted that many ML techniques (predominantly SVMs) used in prediction modeling can accurately predict the conversion from MCI to AD, with most studies using neuroimaging data.<sup>71</sup> However, more recently, methods such as ensemble-based approaches<sup>72</sup> and deep learning<sup>73</sup> are being used to predict future risk decades in advance. In addition, ML can be used to assess the relative importance of multiple risk factors in determining future cognitive impairment and dementia.<sup>74</sup> ML methods are also being developed that improve understanding<sup>72</sup> for the non-ML expert and, therefore, have the potential to improve clinical detection and timely intervention.

## 2.2 | Major current challenges

### 2.2.1 | Understanding risk-factor mechanisms and interactions that contribute to dementia risk

Improved understanding of the causal biological pathways that link risk factors to dementia is required to support the design of preventative interventions and the identification of treatment targets for preserving brain health during early disease stages. Risk factors are likely to exert their effects through a range of distinct biological pathways including those related to protein production and clearance, vascular health, inflammation, and cognitive and neural reserve.<sup>8</sup> However,

the complex etiology of these risk factors coupled with high levels of comorbidity<sup>75</sup> make it hard to pinpoint what the most efficacious mechanistic targets might be, and increase the likelihood that the key target will change between individuals, thereby increasing the need for reliable precision medicine for dementia prevention.

Although the main risk factors for dementia are common and frequently coexist, studies<sup>76</sup> typically focus on a single risk factor or a small group of phenotypically similar factors, leaving networks of interactions and synergistic effects unquantified.<sup>8</sup> However, the direct relationships between large numbers of observed traits can be achieved using network analysis. For example, one study used weighted gene correlation network analysis to identify modules of metabolites that are associated with cognition in late life, some of which seemed to be influenced by risk factors such as education.<sup>77</sup> This highlights the potential value of network-based approaches to identify complex biological pathways that act as mediators between modifiable risk factors and dementia, which could represent realistic therapeutic targets on which to intervene in a clinical trial setting. Integration of deep learning into network analysis, such as DeepPPI, has been shown to outperform traditional methods in predicting interactions within complex networks.<sup>78,79</sup> A study that used unsupervised ML methods applied across multimodal health data successfully identified novel cardiometabolic markers linked to hypertension and poor metabolic health.<sup>80</sup> Use of similar network-based methods for other dementia risk factors could, therefore, help to identify the mechanisms that underlie known epidemiologic associations.

Furthermore, we currently have a poor understanding of the shared biology between dementia risk factors and their impact on brain health, even though shared pathways across risk factors represent promising targets for intervention. However, a study that applied genomic structural equation modeling to AD and 12 modifiable risk factors found high levels of genetic overlap between most dementia risk factors, suggesting that there are overarching shared biological pathways that might increase AD risk.<sup>81</sup> These findings demonstrate the potential merits of using latent variable modeling (LVM) to reduce data complexity and identify common mechanistic patterns between risk factors, but traditional LVM methods perform poorly with highly complex and nonlinear data.<sup>82</sup> In contrast, LVM methods that are based on deep learning approaches, such as autoencoders (AEs), deep neural networks (DNNs), or generative adversarial networks (GANs), are better suited to these kind of data and represent a promising avenue for more accurately defining the shared biology between dementia risk factors.<sup>82,83</sup>

### 2.2.2 | Understanding risk-factor causality and trajectories of dementia risk

Preventing dementia through targeting modifiable risk factors is predicated on the risk factors causally influencing the development of dementia. Therefore, to prevent dementia most effectively we need to determine if these risk factors are causal. The issue is that observational associations between risk factors and dementia could also be due

to shared causality, confounding, or reverse causality.<sup>84,85</sup> Examples of this include possible confounding between education and socioeconomic status, which make it unclear which might be more important as a causal influence on dementia risk,<sup>86</sup> and preclinical effects of AD on hearing and depression, which could indicate reverse causality.<sup>87,88</sup>

A method that is used increasingly to assess the causality of risk factors is Mendelian randomization (MR), which uses genetic variants that are associated with an exposure as instrumental variables to assess the causal influence of the exposure on an outcome. A systematic review<sup>85</sup> of dementia-related MR studies highlighted causal evidence for smoking quantity, vitamin D, homocysteine, systolic blood pressure, fasting glucose, insulin sensitivity, and high-density lipoprotein cholesterol with AD. Other MR studies have also shown causal relationships between cognitive ability, education, and dementia.<sup>89</sup> However, recent MR evidence has provided limited and inconclusive evidence of causal relationships of the modifiable risk factors presented by the Lancet Commission with dementia.<sup>90,91</sup> This may be in part due to effects of survival bias, particularly for risk factors that are significantly associated with earlier mortality, as well as loss of power due to heterogeneity in both the dementia outcome measure and risk-factor exposures. A description of these issues relating to MR and the potential for ML to help alleviate some of these problems in dementia prevention research is discussed in detail in the genetics and omics article also included in this special issue.<sup>48</sup>

However, these shortcomings necessitate the application and triangulation of other causal modeling methods to help us make more confident conclusions about whether a risk factor is causal for dementia, which we focus on in this review. Other methods for causal inference include pathway or mediation analysis. This type of analysis has been used to show a causal role for a range of health and lifestyle factors in mediating the link between socioeconomic status and dementia risk.<sup>92</sup> Mediation analysis is demanding in terms of power and large sample sizes,<sup>93</sup> but ML methods have the potential to help make this type of inference more feasible in dementia prevention research. For example, deep learning assisted methods have been developed recently to identify mediators in high-dimensional data, such as functional imaging or complex population survey data. These have been shown to be successful in identifying brain connectivity networks that mediate the relationship between cognitive traits<sup>94</sup> and in assessing the causal link between health insurance coverage and general health in the United States, even in the presence of multiple confounders.<sup>95</sup>

An alternative approach to inferring causality involves analyzing the timing and trajectory of risk factors: those with a causal effect are likely to show increasing levels of dementia risk with greater duration and intensity of exposure. This approach has been used to demonstrate that depression may be a dementia prodrome rather than a causal risk factor, as it is most associated with dementia risk when occurring for the first time in the period immediately prior to dementia diagnosis.<sup>96</sup> Analysis of the timing and trajectories of risk factors requires either large longitudinal cohorts, such as in recent work showing the most important age range for a deleterious effect of hypertension<sup>97</sup> or improved ability to analyze routinely collected elec-

tronic health records, which is likely to be facilitated by advances in text mining<sup>98</sup> and ML.<sup>99,100</sup> Recent examples of text mining of notes from health records using natural language processing<sup>101</sup> allow for neural network ML architectures to be developed to extract clinical, lifestyle, and pharmacological data. These methods could be applied to analyze the trajectories of how risk factors influence dementia risk over time to support the design of preventative interventions that could be implemented across the life-course of an individual.

## 2.3 | Opportunities and future directions for ML to understand modifiable risk-factor research for dementia prevention

### 2.3.1 | Utilizing multimodal data to understand dementia

The variety of existing data modalities acquired in research and health care can help to provide a more complete picture about a complex disease, such as dementia, than any one type of data on its own. Dementia pathogenesis and clinical progression is hugely heterogeneous between individuals, so the collection of rich and deeply phenotyped, high-dimensional multimodal data is crucial for successful dementia prevention. By integrating and analyzing multimodal data such as omics, histology, imaging, clinical, and digital data, this can unveil novel mechanistic insights that could be used to understand the condition and predict risk across the whole population or specific subgroups.<sup>102,103</sup> This could then lead to a patient-specific approach leading to personalized preventative interventions and specific risk-management strategies for dementia prevention.<sup>104</sup>

ML approaches are well suited to dealing with the high-dimensional nature of multimodal data.<sup>105,106</sup> Multimodal patient data better reflect clinical practice, in which medical histories, fluid biomarkers, genetics, neuropsychology, and structural and functional imaging may all be collected during diagnostic assessments in secondary care. Indeed, several dementia risk scores, such as the CAIDE risk score<sup>69</sup> described in Section 2.1.2, use this sort of information to identify modifiable risk factors that can be managed in mid-life to prevent or delay dementia in later life. Whether ML methods can improve dementia risk prediction has not yet been well studied. One study found a supervised ML model (Disease State Index) to achieve similar sensitivity and specificity to CAIDE in predicting dementia 10 years later.<sup>107</sup> By using data already routinely collected in clinical settings, risk scores and ML algorithms could easily be clinically translatable. On the other hand, the integration of many different data modalities, for example, genetic, multiomic, and advanced neuroimaging features,<sup>108</sup> may improve sensitivity and specificity, but this may be at the expense of clinical translatability and would require a higher level of resources, which are often not available to many populations.

Furthermore, although the use of ML approaches may enhance the analysis of high-dimensional multimodal data, this often leads to increasingly complex models becoming uninterpretable.<sup>109</sup> A good

example of this is DNNs, which are powerful and flexible in practice, although incorporate hidden layers, which have led them to be described as a “black box” technique. These limitations should be thoughtfully considered during the development of any ML model aimed at assisting clinical decision-making. Explainable ML is a burgeoning field that aims to promote easy interpretation of ML models.<sup>110</sup> For example, a recent study created a deep learning framework using multimodal data (magnetic resonance imaging [MRI] and clinical variables). The deep learning framework linked a fully convolutional network to a traditional multilayer perceptron to intuitively visualize and predict AD risk.<sup>111</sup> The model was validated across three independent data sets and could be easily used by practicing neurologists, providing a clinically translatable and interpretable tool using widely collected multimodal data.

In any case, the optimal use of multimodal data for dementia prevention requires triangulation of heterogeneous data all bringing their own unique issues in terms of noise, missingness, and quality.<sup>112</sup> Data labeling becomes challenging in multimodal data sets, with the degree of accuracy or objectivity varying between modalities. For example, some risk factors based on genetics or blood biomarkers may be deemed more objective than features that typically require manual labeling, such as intricate lesions, or that incorporate subjective decision-making, such as behavioral ratings.

Additional challenges, such as data linkage across several data sources, can pose a common barrier to ML because different data modalities vary widely in their availability, accessibility, and generalizability. There have been some recent initiatives to help facilitate cross-cohort access, such as the creation of Dementia Platforms UK Data Portal,<sup>113</sup> however, to promote the application of ML methodologies creating a suitable research infrastructure that makes this feasible is key. Multimodal data also increase the likelihood of being able to identify an individual, as specific combinations of data may be truly unique, which raises ethical issues especially in relation to future dementia risk.<sup>114</sup> Therefore, as ML becomes more routinely applied within dementia prevention research, it will become necessary to create relevant policy and legal regulations that seek to protect individuals while enabling research. Although the use of ML approaches may enhance the analysis of high-dimensional multimodal data, this often comes at a cost with increasingly complex models becoming uninterpretable.<sup>109</sup> A good example of this are DNNs, which are powerful and flexible in practice, although incorporate hidden layers, which have led it them be described as a “black box” technique. Explainable ML is a burgeoning field, aiming to allow interpretation of ML models and is further discussed in Section 4.<sup>110</sup> For example, a recent study created a deep learning framework using multimodal data (MRI and clinical variables). The deep learning framework linked a fully convolutional network to a traditional multilayer perceptron to intuitively visualize and predict AD risk.<sup>111</sup> The model was validated across three independent data sets and could be used easily by practicing neurologists, providing a clinically translatable and interpretable tool using widely collected multimodal data. Despite these challenges, multimodal data combined with ML approaches have considerable potential

to provide further insights into the natural progression of dementia and its risk factors.

### 2.3.2 | Applying multidisciplinary approaches from other research fields

Applying multidisciplinary approaches from other fields can significantly enhance the use of ML for dementia prevention research by providing fresh perspectives, innovative methodologies, and a broader range of expertise.

For example, to improve our ability to recruit participants at risk of developing dementia, it is important to identify individuals at risk with high accuracy over different timescales (months, 2 years, and so on). ML methods have been shown to be effective in predicting short-term risk in other disciplines, such as the prediction of hypoxemia during surgery,<sup>115</sup> and identifying optimal timing to refer patients with terminal respiratory failure for lung transplantation.<sup>116</sup> Much longer timescales are required to utilize these ML methods for primary dementia prevention, and this could be a challenge. However, studies have shown ML to improve the prediction of risk of other long-term conditions and related outcomes such as cardiovascular disease<sup>117,118</sup> and suicide,<sup>119</sup> highlighting the ML potential. ML approaches to identify risk markers or factors are already used successfully for analyses of dementia-related neuroimaging data.<sup>71,120</sup> However, approaches that identify new risk markers/factors temporally preceding the health outcomes would be advantageous, due to the long prodromal period of dementia. Such methods have been used previously to detect early metabolite markers as risk factors for type 2 diabetes.<sup>121</sup> Already known or new risk factors can then be evaluated with ML for causal inference,<sup>122</sup> and there are examples of its use in prenatal and perinatal care.<sup>123</sup> Identifying causal risk factors will allow for targeted risk-reduction interventions for primary dementia prevention, and there are examples of ML being used to target high-risk individuals for cancer screening<sup>124</sup> and suicide prevention.<sup>125</sup>

A shift in focus is required to embed causal applications of ML and other methods in dementia research, by combining domain knowledge to apply ML for causal inference applied in health care, development economics, and other fields.<sup>122</sup> To understand how to prevent dementia, causal ML methodology embedding multidisciplinary approaches is needed, which, can lead to more robust estimates compared to traditional inferential statistics.<sup>122</sup> A major issue is that many studies use predictive ML when researchers are really interested in understanding the underlying pathological and mechanistic processes.

The use of ML could also be used to directly evaluate and compare interventions, which would be beneficial for interventions for risk-factor management in dementia. The application of ML methods in this way has been used to compare therapies for depression using elastic net regularization,<sup>126</sup> and methods such as Bayesian Additive Regression Trees (BART) and regression adjustment on multivariate spline of generalized propensity scores (RAMS), have been used evaluate different surgery types for treatment of non-small cell lung cancer.<sup>127</sup>



### 3 | USE OF ML TO ENHANCE PREVENTION INTERVENTIONS AND TRIALS

In this section we describe what pharmacological or non-pharmacological interventions are available currently to prevent or delay dementia. Second, we state the main challenges in the field such as targeted clinical trial recruitment and testing suitable interventions. Finally, we use examples to highlight how ML can improve personalized medicine in terms of risk-factor management and predicting treatment response, as well as the identification of potential drug candidates for drug repurposing for dementia prevention.

#### 3.1 | State of the science

##### 3.1.1 | Pharmacological and non-pharmacological interventions for dementia

Pharmacological and non-pharmacological interventions will both be key to preventing dementia. However, problems with a lack of understanding of disease complexity, disease heterogeneity, and timing of interventions have resulted in limited progress. Recently, there has been some hope with the approvals of aducanumab and lecanemab by the US Food and Drug Administration (FDA) for treatment of AD in the United States, but there has been much criticism over their effectiveness and severe side effects.<sup>128–132</sup>

Most pharmacological interventions that are being tested currently in dementia clinical trials are disease-modifying therapies, which aim to slow or stop disease progression in early stages. As of January 2023, there are 141 drug candidates being tested in 187 ongoing AD trials. Of these candidates, 28% represent agents that are being repurposed from use for other diseases, aimed at various biological targets with diverse mechanisms of action. There are currently five primary prevention trials in Phase 3 and four prevention trials in Phase 2 enrolling participants with preclinical AD or patients with varying levels of MCI and AD severity.<sup>133</sup>

Regarding non-pharmacological interventions, multiple studies have reported physical activity, cognitive reserve,<sup>134</sup> Mediterranean diet,<sup>135</sup> antioxidants,<sup>136,137</sup> and some vitamins (e.g., vitamin D<sup>138,139</sup>) as protective factors for the development of dementia. This evidence paved the way for randomized clinical trials to determine whether these non-pharmacological interventions may prevent cognitive decline in healthy older people,<sup>140</sup> or those with MCI.<sup>141</sup> The FINGER study reported that a multidomain intervention encompassing diet, exercise, cognition, and vascular risk management improved cognition regardless of participants' characteristics in comparison to regular health advice.<sup>142</sup> Therefore, combining non-pharmacological treatments may be more effective for primary prevention trials. The extension of the FINGER model over 25 countries worldwide will offer important information on the role of multidomain

lifestyle interventions as effective preventative strategies for cognitive decline.<sup>143</sup>

#### 3.2 | Remaining challenges of prevention interventions and trials

##### 3.2.1 | Difficulties with representative targeted recruitment for clinical trials

The lack of representation of minority groups in clinical research remains a significant obstacle in medical research<sup>144</sup> and is not isolated to the dementia field, which affects the usefulness of ML methods to generalize to different sub populations to be used for targeted recruitment to clinical trials. The lack of representation is due in part to the ethical challenges of recruiting people with dementia for secondary prevention clinical trials, with a tendency to paternalistically protect them from harms of participating in research.<sup>145</sup> However, this has been addressed by embedding research in clinical care and streamlining proxy and advanced consent procedures.<sup>138</sup> In addition, the continued lack of representative real-world data has meant dementia risk scores that could be used to identify those at risk of dementia for potential primary prevention trials in those with preclinical dementia are not robustly validated<sup>146</sup> again leading to clinical trials that are unrepresentative,<sup>147</sup> and based upon skewed biomarker data that hinder dementia prevention drug development.<sup>148</sup> The lack of representation of minority groups often leads to bias in ML models, which are then unable to generalize to other populations to identify those who could be targeted and recruited for clinical trials. Further discussion of bias in ML can be found in Section 4 (Limitations of ML for dementia prevention).

##### 3.2.2 | Problems with interventions targeting individual risk factors

Population-level interventions shift the distribution of health risk by addressing the underlying social, economic, and environmental conditions.<sup>149</sup> The high prevalence of modifiable factors for dementia raises the question of whether population-based prevention strategies could reduce the prevalence of dementia. Studies have shown that population level interventions such as those focused on single risk factors, such as maintaining cardiovascular health, have been thought to have contributed to a modest reduction of dementia incidence in some countries.<sup>11</sup> However, dementia risk factors vary among individuals due to genetic, lifestyle, and environmental factors, making it difficult to design a one-size-fits-all population intervention. Furthermore, there are complex interactions between risk factors, and many cluster together<sup>8,53</sup>; therefore, interventions that target more than one risk factor and studies that investigate additive or even synergistic effects of risk factors are likely to be more appropriate than single

interventions for dementia prevention.<sup>150</sup> The challenge of how to develop personalized risk profile management and interventions to address individual variation remains.

### 3.3 | Opportunities and future directions for ML to enhance prevention interventions and trials

#### 3.3.1 | Personalizing preventative interventions

Prevention strategies should begin early and continue throughout life, with public health programs, individually tailored interventions, and the need to tackle inequality given that many risk factors are linked to socioeconomic inequalities.<sup>8</sup> ML could be valuable in gathering information and learning from broad data sets, including from existing medical records, which could be used to model trajectories and develop algorithms for personalized risk planning and management.<sup>151–156</sup> Dementia prevention needs to be able to answer a range of questions, both in individuals with no cognitive impairment (preclinical cases), those with mild memory problems, those who convert from MCI to dementia, and those diagnosed with dementia. There would also be a benefit for ML approaches that can support the integration of biological, psychological, and social factors when approaching diagnosis, classification, prognosis, and tracking of disease progression and its management.

A recent example used transfer learning with ensemble learning algorithms to develop a personalized prediction model that allowed the early detection and prediction of dementia risk. It is important to note that this approach had the ability to visualize the interaction of the risk factors that drove the prediction, which will be vital for risk-factor management and therefore has promising clinical utility.<sup>72</sup> Understanding how aging impacts these ML models is vital, given that diseases that underpin dementia often start in mid-life, and, therefore, how modifiable risk factors interact with their progression may also vary with age.<sup>157</sup>

Some dementia studies are already collecting large and phenotypically deep data sets involving multimodal, cognitive data, language, novel and validated biomarkers, genomics, medical comorbidities, wearable technologies, and imaging.<sup>158</sup> The collection of diverse data such as gait and speech allow for the applications of methods such as SVMs, random forest, and k-nearest neighbors (KNN) algorithms to predict different types of MCI<sup>159</sup> and to differentiate between cognitively normal, MCI, and AD patients.<sup>160</sup>

#### 3.3.2 | Drug repurposing

Drug repurposing encompasses the identification of new uses for drugs beyond the scope of their original indication and can enhance traditional drug development efforts.<sup>161</sup> Identification of repurposing candidates could accelerate the identification of new treatments to modify or slow the onset of dementia as has been the case for cancer, Parkinson's disease, HIV, and other conditions.<sup>162</sup> For dementia

prevention, there are numerous examples of drugs used to treat conditions such as hypertension, diabetes, and rheumatoid arthritis that are associated with a reduced dementia risk.<sup>163–165</sup>

Drug repurposing has been largely opportunistic. However, with the large number of drugs currently on the market or under investigation, and the increasing wealth of data available, ML methods could be a powerful tool in drug repurposing.<sup>166</sup> For example, one study identified drug candidates using ML methods such as logistic regression, SVMs, boosted random forest models, and neural networks applied to gene expression data sets from neuronal cells and postmortem brains of individuals with different stages of AD. From this they identified drug candidates that target Janus kinases, which play a role in immune response, as potential repurposing candidates for AD.<sup>167</sup>

Other methods such as deep learning<sup>168</sup> and network-based approaches<sup>169,170</sup> will be vital to identify and test new potential drug-repurposing candidates for dementia prevention. There is potential for ML methods such as neural networks to identify combinations of drugs that target multiple risk factors simultaneously. It is notable that deep learning could also help elucidate why certain drugs reduce risk mechanistically, which will help with understanding the causes of dementia and identify potential new drug targets.<sup>167,171</sup>

#### 3.3.3 | Predicting treatment response

Prediction of treatment response for an individual patient remains an important goal. With no specific biomarkers being used in routine clinical practice, selecting medications for dementia or other diseases would remain a largely trial-and-error process. ML algorithms that suggest appropriate treatments based on individual patient characteristics are useful, particularly when several treatment options of generally equivalent efficacy are available. Successful examples from other disease areas include the ongoing PETRUSHKA study,<sup>172</sup> which builds on network meta-analytic approaches to estimate individual efficacy of antidepressants through aggregate and individual patient data. The aim of the project is to generate a clinical support system that incorporates patient-level data and patient preferences (i.e., relative importance of efficacy and adverse event risk) to generate a ranking list of treatment recommendations.

Further elaboration of this method<sup>173</sup> used anonymized secondary care patient data obtained through UK-CRIS (<https://crisnetwork.co>) to train a recurrent neural network algorithm to predict the most effective treatment for cognitive impairment (i.e., cholinesterase inhibitor or memantine) in patients with dementia. Although in current clinical practice there is little to distinguish between available treatments, the results showed that patients who were prescribed medications according to what was predicted in the ML model had better cognitive performance after 2 years. The promise of these ML approaches and others in other disease areas such as cancer,<sup>174–176</sup> epilepsy,<sup>177</sup> and other mental health conditions<sup>178</sup> make them a primary opportunity to optimize symptomatic and disease-modifying treatments for dementia.

## 4 | LIMITATIONS OF ML FOR DEMENTIA PREVENTION

Although this review highlights the ways in which ML has the potential to enhance our understanding of dementia prevention, there are also several limitations that are important to consider. First, many standard ML methods do not model causality and are purely associative. They are unable to account for reverse causation and are designed to maximize predictive power, and lack the interpretability that would allow for causal modeling, which is preferable for dementia prevention.<sup>179,180</sup> ML models, like any statistical models, rely on the data and assumptions made during their development. ML models are trained on available data, and the relationships between variables in the data can reflect both direct causal relationships and correlations.<sup>179</sup> If reverse causation is present in the data, ML models can potentially learn and capture those relationships as well as identify appropriate features and consider temporal relationships to minimize the potential influence of reverse causation.<sup>181</sup> Broadly speaking, although ML models can assist in identifying potential causal relationships by revealing associations between variables and providing insights into their predictive power, establishing true causality often requires experimental design, domain expertise, and rigorous causal inference methods beyond the scope of ML techniques.<sup>179</sup> There are specific methods within the field of ML that can assist with causal inference.<sup>182,183</sup> Structural causal models, also known as causal graphical models, aim to represent causal relationships among variables explicitly.<sup>184</sup> These models can be learned from data or expert knowledge and can help elucidate the causal pathways in dementia prevention research. Techniques such as Bayesian networks and directed acyclic graphs<sup>185</sup> have been adapted to consider counterfactual reasoning to represent and analyze causal relationships, and a recent study has shown causal Bayesian networks outperform associative algorithms to diagnose disease, particularly for rarer diseases.<sup>186</sup> Other ML methods include causal forests, which combine elements of random forests with causal inference to estimate treatment effects and identify causal relationships.<sup>187</sup> These methods aim to model heterogeneous treatment effects and provide insights into causal relationships while controlling for confounding variables. They can be useful in identifying factors or interventions that may have a causal impact on dementia outcomes.<sup>188,189</sup> However, a limitation of causal ML for dementia is that the risk factors consist of intricate causal relationships involving different interactive processes, which change over time. Capturing such complexity within a causal model will be a challenge for dementia, and simplified models may not fully capture the underlying causal mechanisms. Furthermore, the lack of interpretability is a common issue and a major limitation for some ML methods such as deep learning, which may also limit clinical acceptability even with causal adaptations.<sup>190–192</sup>

Second, another important limitation is biased ML models (algorithmic bias), which can arise when the ML models are trained on data that are of poor quality or unrepresentative, which can lead to further disadvantages in already under-represented and marginalized groups, thereby worsening existing inequity in health care.<sup>193</sup>

This is particularly poignant for dementia prevention, as evidence suggests that dementia is more prevalent in minority groups who have a younger age of disease onset.<sup>194,195</sup> However, most ML models are based on data from studies incorporating people of European ancestry; therefore, ML models can have poor predictability and generalizability to different subgroups in the population.<sup>196,197</sup> However, with appropriate data-preprocessing techniques and hyperparameter tuning for ML methods such as deep learning, biases can be reduced, resulting in better predictive accuracy achieved for subgroups of the population.<sup>197</sup>

Third, overfitting and underfitting are major issues for all ML models. Overfitting occurs when a model is overtrained to the training data, so it does not generalize to new data sets. Various methods can be implemented to avoid overfitting such as penalties for increasing model complexity and cross validation.<sup>198</sup> Underfitting is the opposite of overfitting and where ML models cannot capture the underlying trends and variability of the data and lack predictive power.<sup>199</sup> Therefore, the training and development of ML models often require a large data set, model optimization, and suitable model validation.<sup>200</sup>

Finally, due to the black-box nature of many ML models, there can be difficulty in the understanding and interpretation and therefore lack of acceptance and usage.<sup>201,202</sup> Consequently, there is a need to provide understandable and transparent explanations for ML model decisions.<sup>203</sup> ML methods and tools such as Shapley,<sup>204</sup> Local Interpretable Model agnostic Explanations (LIME),<sup>205</sup> and glass box methods such as Explainable Boosting Machine<sup>206</sup> can begin to overcome challenges of lack of interpretability of ML models to help provide transparency, trust, and insights into the risk factors and indicators contributing to the development and progression of dementia as well as assisting in early detection, personalized interventions, and informed decision-making for individuals at risk.

## 5 | CONCLUSIONS

A wide range of potentially modifiable risk factors for dementia have been identified across the lifespan. However, the optimal combination of risk factors, possible interactions between them and with genetic risk, and their causal status remain largely unknown. Better risk-prediction tools are needed if personalized dementia prevention interventions are to be delivered in the future. Interpretable and causal ML models may refine our understanding of risk factors and could be used to reduce costs and improve the efficiency and power of future clinical trials. ML frameworks are also being developed to inform AD drug-repurposing efforts and the prioritization of potentially disease-modifying therapeutics. With the increasing complex multimodal becoming available, it is more important to combine different data to not only identify drug repurposing opportunities but also to understand the mechanisms of disease. It is vitally important that challenges relating to infrastructure, data accessibility, and ML acceptance are overcome. If we can overcome these challenges then the true potential of ML for dementia prevention will be realized, leading to precision dementia prevention.

## AUTHOR CONTRIBUTIONS

D.N. contributed to the conception of the work, coordinating the writing team, and drafting and revision of the manuscript for intellectual content. V.O., C.R.M., C.P.A., S.T., V.R., M.V., I.K., S.B., D.W., I.F.F., M.B., A.K.L., E.Y.H.T., and X.Y.T. contributed to drafting and revision of the manuscript for intellectual content. J.M.R. and D.J.L. contributed to the conception of the work, conceived and organized the symposium from which this paper and others in the series originated, revised the manuscript for intellectual content, and harmonized the manuscript with other papers in the series. I.L. contributed to drafting and revision of the manuscript for intellectual content and harmonized the manuscript with other papers in the series. All authors read and approved the final manuscript.

## ACKNOWLEDGMENTS

With thanks to the Deep Dementia Phenotyping (DEMON) Network State of the Science symposium participants (in alphabetical order): Peter Bagshaw, Robin Borchert, Magda Bucholc, James Duce, Charlotte James, David Llewellyn, Donald Lyall, Sarah Marzi, Danielle Newby, Neil Oxtoby, Janice Ranson, Tim Rittman, Nathan Skene, Eugene Tang, Michele Veldsman, Laura Winchester, and Zhi Yao. This review was facilitated by the Alzheimer's Association International Society to Advance Alzheimer's research and Treatment (ISTAART), through the AI for Precision Dementia Medicine Professional Interest Area (PIA). The views and opinions expressed in this publication represent those of the authors and do not necessarily reflect those of the PIA membership, ISTAART, or the Alzheimer's Association. This article was the product of a DEMON Network State of the Science symposium entitled "Harnessing Data Science and AI in Dementia Research" funded by Alzheimer's Research UK. J.M.R. and D.J.L. are supported by Alzheimer's Research UK and the Alan Turing Institute/Engineering and Physical Sciences Research Council (EP/N510129/1). D.J.L. also receives funding from the Medical Research Council (MR/X005674/1), National Institute for Health Research (NIHR) Applied Research Collaboration South West Peninsula, National Health and Medical Research Council (NHMRC), and National Institute on Aging/National Institutes of Health (RF1AG055654). This work was additionally supported by the following: European Research Council (grant agreement no. 803239 (A.K.L.), Barts Charity (C.R.M.), George Henry Woolfe Legacy Fund and the National Institute on Aging (RF1AG073593) (I.F.F.), E.Y.H.T. (National Institute for Health Research (NIHR) Clinical Lecturer) is funded by the NIHR and the views expressed in this publication are those of the author(s) and not necessarily those of the NIHR, NHS, or the UK Department of Health and Social Care. S.B. is supported by Dementias Platform UK (DPUK). The Medical Research Council supports DPUK through grant MR/T0333771. M.B. is supported by Alzheimer's Research UK, Economic and Social Research Council (ES/W010240/1), EU (Special EU Programmes body (SEUPB)) INTER-REG (European Region Development Fund (ERDF)/SEUPB), Health and Social Care Research and Development HSC R&D (COM/5750/23) and Dr George Moore Endowment for Data Science at Ulster University.

## CONFLICT OF INTEREST STATEMENT

V.O. is a commissioner of the 2017 and the 2020 Lancet Commission on dementia prevention, intervention, and care. D.C.W. has served on advisory boards with Roche, Biogen, and Merck. V.R. has provided consultancy to Biogen. A.K.L. has served on advisory boards with Roche. DPUK is a DEMON partner. All other authors declare no conflicts of interest. Author disclosures are available in the [Supporting information](#).

## ORCID

Danielle Newby  <https://orcid.org/0000-0002-3001-1478>

## REFERENCES

1. Matthews FE, Stephan BC, Robinson L, et al. A two decade dementia incidence comparison from the Cognitive Function and Ageing Studies I and II. *Nat Commun*. 2016;7:11398. doi:[10.1038/NCOMMS11398](https://doi.org/10.1038/NCOMMS11398)
2. Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. *N Engl J Med*. 2016;374:523-532. doi:[10.1056/NEJMOA1504327](https://doi.org/10.1056/NEJMOA1504327)
3. Martin Prince A, Wimo A, Guerchet M, et al. World Alzheimer Report 2015. The global impact of dementia an analysis of prevalence, incidence, cost and trends. 2015. <https://www.alzint.org/u/WorldAlzheimerReport2015.pdf>
4. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol*. 2017;134:171-186. doi:[10.1007/s00401-017-1717-7](https://doi.org/10.1007/s00401-017-1717-7)
5. Beason-Held LL, Goh JO, An Y, et al. Changes in brain function occur years before the onset of cognitive impairment. *J Neurosci*. 2013;33:18008-18014. doi:[10.1523/JNEUROSCI.1402-13.2013](https://doi.org/10.1523/JNEUROSCI.1402-13.2013)
6. Zissimopoulos J, Crimmins E, Stclair P. The value of delaying Alzheimer's disease onset. *Forum Health Econ Policy*. 2014;18:25. doi:[10.1515/FHEP-2014-0013](https://doi.org/10.1515/FHEP-2014-0013)
7. Beeri MS. Prevention of dementia presents a potentially critical platform for improvement of long-term public health. *Dialogues Clin Neurosci*. 2019;21:93. doi:[10.31887/DCNS.2019.21.1/MBEERI](https://doi.org/10.31887/DCNS.2019.21.1/MBEERI)
8. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396:413-446. doi:[10.1016/S0140-6736\(20\)30367-6](https://doi.org/10.1016/S0140-6736(20)30367-6)
9. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet*. 2015;385:2255-2263. doi:[10.1016/S0140-6736\(15\)60461-5](https://doi.org/10.1016/S0140-6736(15)60461-5)
10. Minghui R. WHO Guidelines—Risk reduction for cognitive decline and dementia. Risk reduction of cognitive decline and dementia 2019:96. ISBN: 978 92 4 155054 3. <https://www.who.int/publications/i/item/9789241550543>
11. Eggink E, van Charante EPM, van Gool WA, Richard E. A population perspective on prevention of dementia. *J Clin Med*. 2019;8:834. doi:[10.3390/JCM8060834](https://doi.org/10.3390/JCM8060834)
12. Rakesh G, Szabo ST, Alexopoulos GS, Zannas AS. Strategies for dementia prevention: latest evidence and implications. *Ther Adv Chronic Dis*. 2017;8:121-136. doi:[10.1177/2040622317712442](https://doi.org/10.1177/2040622317712442)
13. James C, Ranson JM, Everson R, Llewellyn DJ. Performance of machine learning algorithms for predicting progression to dementia in memory clinic patients. *JAMA Netw Open*. 2021;4:e2136553-e2136553. doi:[10.1001/JAMANETWORKOPEN.2021.36553](https://doi.org/10.1001/JAMANETWORKOPEN.2021.36553)
14. Eckhardt CM, Madjarova SJ, Williams RJ, et al. Unsupervised machine learning methods and emerging applications in healthcare.



- Knee Surg Sports Traumatol Arthrosc.* 2023;31:376-381. doi:[10.1007/S00167-022-07233-7](https://doi.org/10.1007/S00167-022-07233-7)
15. Deo RC. Machine learning in medicine. *Circulation.* 2015;132:1920. doi:[10.1161/CIRCULATIONAHA.115.001593](https://doi.org/10.1161/CIRCULATIONAHA.115.001593)
16. Gamberger D, Lavrač N, Srivatsa S, Tanzi RE, Doraiswamy PM. Identification of clusters of rapid and slow decliners among subjects at risk for Alzheimer's disease. *Sci Rep.* 2017;7:1-12. doi:[10.1038/s41598-017-06624-y](https://doi.org/10.1038/s41598-017-06624-y)
17. Calvin CM, Conroy MC, Moore SF, Kuźma E, Littlejohns TJ. Association of multimorbidity, disease clusters, and modification by genetic factors with risk of dementia. *JAMA Netw Open.* 2022;5:e2232124-e2232124. doi:[10.1001/JAMANETWORKOPEN.2022.32124](https://doi.org/10.1001/JAMANETWORKOPEN.2022.32124)
18. Bijlani N, Nilforooshan R, Kouchaki S. An unsupervised data-driven anomaly detection approach for adverse health conditions in people living with dementia: cohort study. *JMIR Aging.* 2022;5:e38211. doi:[10.2196/38211](https://doi.org/10.2196/38211)
19. Goldstein M, Uchida S. A comparative evaluation of unsupervised anomaly detection algorithms for multivariate data. *PLoS One.* 2016;11:e0152173. doi:[10.1371/JOURNAL.PONE.0152173](https://doi.org/10.1371/JOURNAL.PONE.0152173)
20. Nezhadmoghadam F, Martinez-Torteya A, Treviño V, et al. Robust discovery of mild cognitive impairment subtypes and their risk of Alzheimer's disease conversion using unsupervised machine learning and gaussian mixture modeling. *Curr Alzheimer Res.* 2021;18:595-606. doi:[10.2174/1567205018666210831145825](https://doi.org/10.2174/1567205018666210831145825)
21. Shao Y, Zeng QT, Chen KK, Shutes-David A, Thielke SM, Tsuang DW. Detection of probable dementia cases in undiagnosed patients using structured and unstructured electronic health records. *BMC Med Inform Decis Mak.* 2019;19:1-11. doi:[10.1186/S12911-019-0846-4/TABLES/5](https://doi.org/10.1186/S12911-019-0846-4/TABLES/5)
22. Sidey-Gibbons JAM, Sidey-Gibbons CJ. Machine learning in medicine: a practical introduction. *BMC Med Res Methodol.* 2019;19:1-18. doi:[10.1186/S12874-019-0681-4/TABLES/5](https://doi.org/10.1186/S12874-019-0681-4/TABLES/5)
23. Alpaydin E. *Introduction to Machine Learning Fourth Edition.* MIT Press; 2020.
24. Goerdten J, Čukić I, Danso SO, Carrière I, Muniz-Terrera G. Statistical methods for dementia risk prediction and recommendations for future work: a systematic review. *Alzheimers Dement.* 2019;5:563. doi:[10.1016/J.TRCI.2019.08.001](https://doi.org/10.1016/J.TRCI.2019.08.001)
25. Li H, Habes M, Wolk DA, Fan Y. A deep learning model for early prediction of Alzheimer's disease dementia based on hippocampal MRI. *Alzheimers Dement.* 2019;15:1059. doi:[10.1016/J.JALZ.2019.02.007](https://doi.org/10.1016/J.JALZ.2019.02.007)
26. Maroco J, Silva D, Rodrigues A, Guerreiro M, Santana I, De Mendonça A. Data mining methods in the prediction of dementia: a real-data comparison of the accuracy, sensitivity and specificity of linear discriminant analysis, logistic regression, neural networks, support vector machines, classification trees and random forests. *BMC Res Notes.* 2011;4:1-14. doi:[10.1186/1756-0500-4-299/FIGURES/8](https://doi.org/10.1186/1756-0500-4-299/FIGURES/8)
27. Costa A, Pais M, Loureiro J, et al. Decision tree-based classification as a support to diagnosis in the Alzheimer's disease continuum using cerebrospinal fluid biomarkers: insights from automated analysis. *Braz J Psychiat.* 2022;44:370. doi:[10.47626/1516-4446-2021-2277](https://doi.org/10.47626/1516-4446-2021-2277)
28. Lin H, Himali JJ, Satizabal CL, et al. Identifying blood biomarkers for dementia using machine learning methods in the Framingham Heart Study. *Cells.* 2022;11:1506. doi:[10.3390/CELLS11091506/S1](https://doi.org/10.3390/CELLS11091506/S1)
29. Ahmed MR, Zhang Y, Feng Z, Lo B, Inan OT, Liao H. Neuroimaging and machine learning for dementia diagnosis: recent advancements and future prospects. *IEEE Rev Biomed Eng.* 2019;12:19-33. doi:[10.1109/RBME.2018.2886237](https://doi.org/10.1109/RBME.2018.2886237)
30. Chang CH, Lin CH, Lane HY. Machine learning and novel biomarkers for the diagnosis of Alzheimer's disease. *Int J Mol Sci.* 2021;22:1-12. doi:[10.3390/IJMS22052761](https://doi.org/10.3390/IJMS22052761)
31. Wu Y, Jia M, Xiang C, Lin S, Jiang Z, Fang Y. Predicting the long-term cognitive trajectories using machine learning approaches: a Chinese nationwide longitudinal database. *Psychiatry Res.* 2022;310:114434. doi:[10.1016/J.PSYCHRES.2022.114434](https://doi.org/10.1016/J.PSYCHRES.2022.114434)
32. van Engelen JE, Hoos HH. A survey on semi-supervised learning. *Mach Learn.* 2020;109:373-440. doi:[10.1007/S10994-019-05855-6/FIGURES/5](https://doi.org/10.1007/S10994-019-05855-6/FIGURES/5)
33. Triguero I, García S, Herrera F. Self-labeled techniques for semi-supervised learning: taxonomy, software and empirical study. *Knowl Inf Syst.* 2015;42:245-284. doi:[10.1007/S10115-013-0706-Y/FIGURES/13](https://doi.org/10.1007/S10115-013-0706-Y/FIGURES/13)
34. Chai H, Liang Y, Wang S, wei ShenH. A novel logistic regression model combining semi-supervised learning and active learning for disease classification. *Sci Rep.* 2018;8:1-10. doi:[10.1038/s41598-018-31395-5](https://doi.org/10.1038/s41598-018-31395-5)
35. Tanha J, van Someren M, Afsarmanesh H. Semi-supervised self-training for decision tree classifiers. *Int J Mach Learn Cybern.* 2017;8:355-370. doi:[10.1007/S13042-015-0328-7/TABLES/11](https://doi.org/10.1007/S13042-015-0328-7/TABLES/11)
36. Blum A, Mitchell T. Combining labeled and unlabeled data with co-training. *Proceedings of the Annual ACM Conference on Computational Learning Theory.* 1998:92-100. doi:[10.1145/279943.279962](https://doi.org/10.1145/279943.279962)
37. Wang Y, Gu X, Hou W, Zhao M, Sun L, Guo C. Dual semi-supervised learning for classification of Alzheimer's disease and mild cognitive impairment based on neuropsychological data. *Brain Sci.* 2023;13:306. doi:[10.3390/BRAINS13020306](https://doi.org/10.3390/BRAINS13020306)
38. Teramoto R. Prediction of Alzheimer's diagnosis using semi-supervised distance metric learning with label propagation. *Comput Biol Chem.* 2008;32:438-441. doi:[10.1016/J.COMPBIOLCHEM.2008.07.030](https://doi.org/10.1016/J.COMPBIOLCHEM.2008.07.030)
39. Bucholc M, James C, Khleifat AA, et al. Artificial intelligence for dementia research methods optimization. *Alzheimers Dement.* 2023;1-18. doi:[10.1002/alz.13441](https://doi.org/10.1002/alz.13441)
40. Sibbett RA, Russ TC, Deary IJ, Starr JM. Risk factors for dementia in the ninth decade of life and beyond: a study of the Lothian birth cohort 1921. *BMC Psychiatry.* 2017;17:1-10. doi:[10.1186/S12888-017-1366-3](https://doi.org/10.1186/S12888-017-1366-3)
41. Song X, Mitnitski A, Rockwood K. Nontraditional risk factors combine to predict Alzheimer disease and dementia. *Neurology.* 2011;77:227-234. doi:[10.1212/WNL.0B013E318225C6BC](https://doi.org/10.1212/WNL.0B013E318225C6BC)
42. Reitz C, Tang M, Schupf N, Manly JJ, Mayeux R, Luchsinger JA. A summary risk score for the prediction of Alzheimer disease in elderly persons. *Arch Neurol.* 2010;67:835-841. doi:[10.1001/ARCHNEUROL.2010.136](https://doi.org/10.1001/ARCHNEUROL.2010.136)
43. Exalto LG, Biessels GJ, Karter AJ, et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. *Lancet Diabetes Endocrinol.* 2013;1:183-190. doi:[10.1016/S2213-8587\(13\)70048-2](https://doi.org/10.1016/S2213-8587(13)70048-2)
44. Deo RC. Machine learning in medicine. *Circulation.* 2015;132:1920-1930. doi:[10.1161/CIRCULATIONAHA.115.001593](https://doi.org/10.1161/CIRCULATIONAHA.115.001593)
45. Oren O, Gersh BJ, Bhatt DL. Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. *Lancet Digit Health.* 2020;2:e486-e488. doi:[10.1016/S2589-7500\(20\)30160-6](https://doi.org/10.1016/S2589-7500(20)30160-6)
46. Marzi SJ, Schilder B, Nott A, et al. Artificial intelligence for neurodegenerative experimental models. *Alzheimers Dement.* Accepted.
47. Doherty T, Yao Z, Khleifat AA, et al. Artificial intelligence for dementia drug discovery and trials optimization. *Alzheimer's Dement.* 2023;1-12. doi:[10.1002/alz.13428](https://doi.org/10.1002/alz.13428)
48. Bettencourt C, Skene N, Bandres-Ciga S, et al. Artificial intelligence for dementia genetics and omics. *Alzheimer's Dement.* 2023;1-17. doi:[10.1002/alz.13427](https://doi.org/10.1002/alz.13427)
49. Winchester LM, Harshfield EL, Shi L, et al. Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia. *Alzheimer's Dement.* 2023;1-12. doi:[10.1002/alz.13390](https://doi.org/10.1002/alz.13390)
50. Borchert RJ, Azevedo T, Badhwar AP, et al. Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review. *Alzheimer's Dement.* 2023;1-20. doi:[10.1002/alz.13412](https://doi.org/10.1002/alz.13412)



51. Lyall DM, Kormilitzin A, Lancaster C, et al. Artificial intelligence for dementia—Applied models and digital health. *Alzheimer's Dement*. 2023;1-13. doi:10.1002/alz.13391
52. Lisko I, Kulmala J, Annetorp M, Ngandu T, Mangialasche F, Kivipelto M. How can dementia and disability be prevented in older adults: where are we today and where are we going? *J Intern Med*. 2021;289:807-830. doi:10.1111/JOIM.13227
53. Livingston G, Sommerlad A, Orgeta V, et al. The Lancet Commissions Dementia prevention, intervention, and care. *Lancet*. 2017;390:2673-2734. doi:10.1016/S0140-6736(17)31363-6
54. Peters R, Booth A, Rockwood K, Peters J, D'Este C, Anstey KJ. Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis. *BMJ Open*. 2019;9:e022846. doi:10.1136/BMJOPEN-2018-022846
55. Deckers K, Van Boxtel MPJ, Schiepers OJG, et al. Target risk factors for dementia prevention: a systematic review and Delphi consensus study on the evidence from observational studies. *Int J Geriatr Psychiatry*. 2015;30:234-246. doi:10.1002/GPS.4245
56. Zhang YR, Xu W, Zhang W, et al. Modifiable risk factors for incident dementia and cognitive impairment: an umbrella review of evidence. *J Affect Disord*. 2022;314:160-167. doi:10.1016/J.JAD.2022.07.008
57. Anstey KJ, Ee N, Eramudugolla R, Jagger C, Peters R. A systematic review of meta-analyses that evaluate risk factors for dementia to evaluate the quantity, quality, and global representativeness of evidence. *J Alzheimers Dis*. 2019;70:S165-S186. doi:10.3233/JAD-190181
58. Bellou V, Bellasis L, Tzoulaki I, Middleton LT, Ioannidis JPA, Evangelou E. Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses. *Alzheimers Dement*. 2017;13:406-418. doi:10.1016/J.JALZ.2016.07.152
59. Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and dementia risk: a systematic review and meta-analysis. *Alzheimers Dement*. 2018;14:1416-1426. doi:10.1016/J.JALZ.2018.06.3061
60. Pereira JVB, Aung Thein MZ, Nitchingham A, Caplan GA. Delirium in older adults is associated with development of new dementia: a systematic review and meta-analysis. *Int J Geriatr Psychiatry*. 2021;36:993-1003. doi:10.1002/GPS.5508
61. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. *Lancet Neurol*. 2013;12:207-216. doi:10.1016/S1474-4422(12)70291-0
62. Hadjichrysanthou C, Evans S, Bajaj S, Siakallis LC, McRae-McKee K, De Wolf F. The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. *Alzheimers Res Ther*. 2020;12:1-16. doi:10.1186/S13195-020-00636-Z/FIGURES/5
63. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA*. 2015;313:1924-1938. doi:10.1001/JAMA.2015.4668
64. Perera G, Rijnbeek PR, Alexander M, et al. Vascular and metabolic risk factor differences prior to dementia diagnosis: a multidatabase case-control study using European electronic health records. *BMJ Open*. 2020;10:e038753. doi:10.1136/BMJOPEN-2020-038753
65. Singh-Manoux A, Dugravot A, Shipley M, et al. Obesity trajectories and risk of dementia: 28 years of follow-up in the Whitehall II Study. *Alzheimers Dement*. 2018;14:178-186. doi:10.1016/J.JALZ.2017.06.2637
66. Sheetal A, Jiang Z, Di Milia L. Using machine learning to analyze longitudinal data: a tutorial guide and best-practice recommendations for social science researchers. *Applied Psychology*. 2023;72:1339-1364. doi:10.1111/APPS.12435
67. Hou XH, Feng L, Zhang C, Cao XP, Tan L, Yu JT. Models for predicting risk of dementia: a systematic review. *J Neurol Neurosurg Psychiatry*. 2019;90:373-379. doi:10.1136/JNNP-2018-318212
68. Tang EYH, Harrison SL, Errington L, et al. Current developments in dementia risk prediction modelling: an updated systematic review. *PLoS One*. 2015;10:e0136181. doi:10.1371/JOURNAL.PONE.0136181
69. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *Lancet Neurol*. 2006;5:735-741. doi:10.1016/S1474-4422(06)70537-3
70. Anatórk M, Patel R, Ebmeier K, et al. Development and validation of a dementia risk score in the UK Biobank and Whitehall II Cohorts. *British Medical Journal Mental Health*. 2023;26:e300719. doi:10.1136/BMJMENT-2023-300719
71. Dallora AL, Eivazzadeh S, Mendes E, Berglund J, Anderberg P. Machine learning and microsimulation techniques on the prognosis of dementia: a systematic literature review. *PLoS One*. 2017;12:e0179804. doi:10.1371/JOURNAL.PONE.0179804
72. Danso SO, Zeng Z, Muniz-Terrera G, Ritchie CW. Developing an explainable machine learning-based personalised dementia risk prediction model: a transfer learning approach with ensemble learning algorithms. *Front Big Data*. 2021;0:21. doi:10.3389/FDATA.2021.613047
73. Stamate D, Smith R, Tsygancov R, et al. Applying deep learning to predicting dementia and mild cognitive impairment. *Artif Intell Appl Innov*. 2020;584:308. doi:10.1007/978-3-030-49186-4\_26
74. Aschwanden D, Aichele S, Ghisletta P, et al. Predicting cognitive impairment and dementia: a machine learning approach. *J Alzheimers Dis*. 2020;75:717-728. doi:10.3233/JAD-190967
75. Kuan V, Denaxas S, Patalay P, et al. Identifying and visualising multimorbidity and comorbidity patterns in patients in the English National Health Service: a population-based study. *Lancet Digit Health*. 2023;5:e16-e27. doi:10.1016/S2589-7500(22)00187-X
76. Hu HY, Zhang YR, Aerqin Q, et al. Association between multimorbidity status and incident dementia: a prospective cohort study of 245,483 participants. *Transl Psychiatry*. 2022;12:1-10. doi:10.1038/s41398-022-02268-3
77. Green R, Lord J, Xu J, et al. Metabolic correlates of late midlife cognitive outcomes: findings from the 1946 British Birth Cohort. *Brain Commun*. 2022;4:fcab291. doi:10.1093/BRAINCOMMS/FCAB291
78. Muzio G, O'Bray L, Borgwardt K. Biological network analysis with deep learning. *Brief Bioinform*. 2021;22:1515-1530. doi:10.1093/BIB/BBAA257
79. Du X, Sun S, Hu C, Yao Y, Yan Y, Zhang Y. DeepPPI: boosting prediction of protein-protein interactions with deep neural networks. *J Chem Inf Model*. 2017;57:1499-1510. doi:10.1021/ACS.JCIM.7B00028/SUPPL\_FILE/CI7B00028\_SI\_001.ZIP
80. Shomorony I, Cirulli ET, Huang L, et al. An unsupervised learning approach to identify novel signatures of health and disease from multimodal data. *Genome Med*. 2020;12:1-14. doi:10.1186/S13073-019-0705-Z/FIGURES/5
81. Foote IF, Jacobs BM, Mathlin G, et al. The shared genetic architecture of modifiable risk for Alzheimer's disease: a genomic structural equation modelling study. *Neurobiol Aging*. 2022;117:222-235. doi:10.1016/J.NEUROBIOLAGING.2022.02.016
82. Kong X, Jiang X, Zhang B, Yuan J, Ge Z. Latent variable models in the era of industrial big data: extension and beyond. *Annu Rev Control*. 2022;54:167-199. doi:10.1016/J.ARCONTROL.2022.09.005
83. Kopf A, Claassen M. Latent representation learning in biology and translational medicine. *Patterns*. 2021;2:100198. doi:10.1016/J.PATTER.2021.100198
84. Selbæk G. Dementia risk: time matters. *Lancet Public Health*. 2021;6:e85-e86. doi:10.1016/S2468-2667(21)00010-4
85. Kuźma E, Hannon E, Zhou A, et al. Which risk factors causally influence dementia? A systematic review of Mendelian

- randomization studies. *J Alzheimers Dis.* 2018;64:181-193. doi:[10.3233/JAD-180013](https://doi.org/10.3233/JAD-180013)
86. Seblava D, Fischer M, Fors S, et al. Does prolonged education causally affect dementia risk when adult socioeconomic status is not altered? A Swedish Natural Experiment in 1.3 million individuals. *Am J Epidemiol.* 2021;190:817-826. doi:[10.1093/AJE/KWAA255](https://doi.org/10.1093/AJE/KWAA255)
87. Johnson JCS, Marshall CR, Weil RS, Bamio DE, Hardy CJD, Warren JD. Hearing and dementia: from ears to brain. *Brain.* 2021;144:391-401. doi:[10.1093/BRAIN/AWAA429](https://doi.org/10.1093/BRAIN/AWAA429)
88. Carles S, Carrière I, Reppermund S, et al. A cross-national study of depression in preclinical dementia: a COSMIC collaboration study. *Alzheimers Dementia.* 2020;16:1544-1552. doi:[10.1002/ALZ.12149](https://doi.org/10.1002/ALZ.12149)
89. Anderson EL, Howe LD, Wade KH, et al. Education, intelligence and Alzheimer's disease: evidence from a multivariable two-sample Mendelian randomization study. *Int J Epidemiol.* 2020;49:1163-1172. doi:[10.1093/IJE/DY2280](https://doi.org/10.1093/IJE/DY2280)
90. Desai R, John A, Saunders R, et al. Examining the Lancet Commission risk factors for dementia using Mendelian randomisation. *BMJ Mental Health.* 2023;26:e300555. doi:[10.1136/BMJMENT-2022-300555](https://doi.org/10.1136/BMJMENT-2022-300555)
91. Luo J, Thomassen JQ, Bellenguez C, et al. Genetic associations between modifiable risk factors and Alzheimer disease. *JAMA Netw Open.* 2023;6:e2313734-e2313734. doi:[10.1001/JAMANETWORKOPEN.2023.13734](https://doi.org/10.1001/JAMANETWORKOPEN.2023.13734)
92. Deckers K, Cadar D, van Boxtel MPJ, Verhey FRJ, Steptoe A, Köhler S. Modifiable risk factors explain socioeconomic inequalities in dementia risk: evidence from a population-based prospective cohort study. *J Alzheimers Dis.* 2019;71:549-557. doi:[10.3233/JAD-190541](https://doi.org/10.3233/JAD-190541)
93. Fritz MS, MacKinnon DP. Required sample size to detect the mediated effect. *Psychol Sci.* 2016;18:233-239. doi:[10.1111/J.1467-9280.2007.01882.X](https://doi.org/10.1111/J.1467-9280.2007.01882.X)
94. Nath T, Caffo B, Wager T, Lindquist MA. A machine learning based approach towards high-dimensional mediation analysis. *Neuroimage.* 2023;268:119843. doi:[10.1016/J.NEUROIMAGE.2022.119843](https://doi.org/10.1016/J.NEUROIMAGE.2022.119843)
95. Farbmacher H, Huber M, Laffers L, Langen H, Spindler M. Causal mediation analysis with double machine learning. *Econom J.* 2022;25:277-300. doi:[10.1093/ECTJ/UTAC003](https://doi.org/10.1093/ECTJ/UTAC003)
96. Demnitz N, Anatórk M, Allan C, et al. Association of trajectories of depressive symptoms with vascular risk, cognitive function and adverse brain outcomes: the Whitehall II MRI sub-study. *J Psychiatr Res.* 2020;131:85-93. doi:[10.1016/J.JPSYCHIRES.2020.09.005](https://doi.org/10.1016/J.JPSYCHIRES.2020.09.005)
97. Lane CA, Barnes J, Nicholas JM, et al. Associations between blood pressure across adulthood and late-life brain structure and pathology in the neuroscience substudy of the 1946 British birth cohort (Insight 46): an epidemiological study. *Lancet Neurol.* 2019;18:942-952. doi:[10.1016/S1474-4422\(19\)30228-5](https://doi.org/10.1016/S1474-4422(19)30228-5)
98. Ford E, Curlew K, Squires E, Griffiths LJ, Stewart R, Jones KH. The potential of research drawing on clinical free text to bring benefits to patients in the United Kingdom: a systematic review of the literature. *Front Digit Health.* 2021;3:606599. doi:[10.3389/FDGH.2021.606599](https://doi.org/10.3389/FDGH.2021.606599)
99. Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. *Nat Rev Genet.* 2012;13:395-405. doi:[10.1038/nrg3208](https://doi.org/10.1038/nrg3208)
100. Auger SD, Jacobs BM, Dobson R, Marshall CR, Noyce AJ. Big data, machine learning and artificial intelligence: a neurologist's guide. *Pract Neurol.* 2021;21:4-11. doi:[10.1136/PRACTNEUROL-2020-002688](https://doi.org/10.1136/PRACTNEUROL-2020-002688)
101. Vací N, Liu Q, Kormilitzin A, et al. Natural language processing for structuring clinical text data on depression using UK-CRIS. *Evid Based Ment Health.* 2020;23:21-26. doi:[10.1136/EBMENTAL-2019-300134](https://doi.org/10.1136/EBMENTAL-2019-300134)
102. Li R, Wang X, Lawler K, Garg S, Bai Q, Alty J. Applications of Artificial Intelligence to aid detection of dementia: a narrative review on current capabilities and future directions. *J Biomed Inform [Internet].* 2022;127:104030.
103. Khodabandehloo E, Riboni D. Collaborative trajectory mining in smart-homes to support early diagnosis of cognitive decline. *IEEE Trans Emerg Top Comput.* 2021;9:1194-1205. doi:[10.1109/TETC.2020.2975071](https://doi.org/10.1109/TETC.2020.2975071)
104. Chen JH, Asch SM. Machine learning and prediction in medicine—beyond the peak of inflated expectations. *N Engl J Med.* 2017;376:2507. doi:[10.1056/NEJMP1702071](https://doi.org/10.1056/NEJMP1702071)
105. Bi XA, Hu X, Wu H, Wang Y. Multimodal data analysis of Alzheimer's disease based on clustering evolutionary random forest. *IEEE J Biomed Health Inform.* 2020;24:2973-2983. doi:[10.1109/JBHI.2020.2973324](https://doi.org/10.1109/JBHI.2020.2973324)
106. Venugopalan J, Tong L, Hassanzadeh HR, Wang MD. Multimodal deep learning models for early detection of Alzheimer's disease stage. *Sci Rep.* 2021;11:1-13. doi:[10.1038/s41598-020-74399-w](https://doi.org/10.1038/s41598-020-74399-w)
107. Pekkala T, Hall A, Löjtönen J, et al. Development of a late-life dementia prediction index with supervised machine learning in the population-based CAIDE study. *J Alzheimers Dis.* 2017;55:1055-1067. doi:[10.3233/JAD-160560](https://doi.org/10.3233/JAD-160560)
108. Zhou T, Thung KH, Zhu X, Shen D. Effective feature learning and fusion of multimodality data using stage-wise deep neural network for dementia diagnosis. *Hum Brain Mapp.* 2019;40:1001-1016. doi:[10.1002/HBM.24428](https://doi.org/10.1002/HBM.24428)
109. El-Sappagh S, Alonso JM, Islam SMR, Sultan AM, Kwak KS. A multilayer multimodal detection and prediction model based on explainable artificial intelligence for Alzheimer's disease. *Sci Rep.* 2021;11:1-26. doi:[10.1038/s41598-021-82098-3](https://doi.org/10.1038/s41598-021-82098-3)
110. Amann J, Blasimme A, Vayena E, Frey D, Madai VI. Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. *BMC Med Inform Decis Mak.* 2020;20:1-9. doi:[10.1186/S12911-020-01332-6](https://doi.org/10.1186/S12911-020-01332-6)
111. Qiu S, Joshi PS, Miller MI, et al. Development and validation of an interpretable deep learning framework for Alzheimer's disease classification. *Brain.* 2020;143:1920-1933. doi:[10.1093/BRAIN/AWAA137](https://doi.org/10.1093/BRAIN/AWAA137)
112. Thung K-H, Yap P-T, Shen D. Multi-stage diagnosis of Alzheimer's Disease with incomplete multimodal data via multi-task deep learning. *Deep Learn Med Image Anal Multimodal Learn Clin Decis Support (2017).* 2017;10553LNCIS:160-168. doi:[10.1007/978-3-319-67558-9\\_19](https://doi.org/10.1007/978-3-319-67558-9_19)
113. Bauermeister S, Orton C, Thompson S, et al. The Dementias Platform UK (DPUK) Data Portal. *Eur J Epidemiol.* 2020;35:601-611. doi:[10.1007/S10654-020-00633-4/TABLES/1](https://doi.org/10.1007/S10654-020-00633-4/TABLES/1)
114. Floridi L, Taddeo M. What is data ethics? *Philos Trans Royal Soc A.* 2016;374:20160360. doi:[10.1098/RSTA.2016.0360](https://doi.org/10.1098/RSTA.2016.0360)
115. Lundberg SM, Nair B, Vavilala MS, et al. Explainable machine-learning predictions for the prevention of hypoxaemia during surgery. *Nat Biomed Eng.* 2018;2:749-760. doi:[10.1038/s41551-018-0304-0](https://doi.org/10.1038/s41551-018-0304-0)
116. Alaa AM, van der Schaar M. Prognostication and risk factors for cystic fibrosis via automated machine learning. *Sci Rep.* 2018;8:11242. doi:[10.1038/S41598-018-29523-2](https://doi.org/10.1038/S41598-018-29523-2)
117. Weng SF, Reps J, Kai J, Garibaldi JM, Qureshi N. Can machine-learning improve cardiovascular risk prediction using routine clinical data? *PLoS One.* 2017;12:e0174944. doi:[10.1371/JOURNAL.PONE.0174944](https://doi.org/10.1371/JOURNAL.PONE.0174944)
118. Alaa AM, Bolton T, Di Angelantonio E, Rudd JHF, van der Schaar M. Cardiovascular disease risk prediction using automated machine learning: a prospective study of 423,604 UK Biobank participants. *PLoS One.* 2019;14:e0213653. doi:[10.1371/JOURNAL.PONE.0213653](https://doi.org/10.1371/JOURNAL.PONE.0213653)
119. Kessler RC, Hwang I, Hoffmire CA, et al. Developing a practical suicide risk prediction model for targeting high-risk patients in the Veterans health Administration. *Int J Methods Psychiatr Res.* 2017;26(3):e1575. doi:[10.1002/MPR.1575](https://doi.org/10.1002/MPR.1575)
120. Borchert RJ, Azevedo T, Badhwar AP, et al. Artificial intelligence for diagnostic and prognostic neuroimaging in dementia: A systematic review. *Alzheimer's Dement.* 2023;1-20. doi:[10.1002/alz.13412](https://doi.org/10.1002/alz.13412)

121. Peddinti G, Cobb J, Yengo L, et al. Early metabolic markers identify potential targets for the prevention of type 2 diabetes. *Diabetologia*. 2017;60:1740-1750. doi:[10.1007/S00125-017-4325-0](https://doi.org/10.1007/S00125-017-4325-0)
122. Leist AK, Klee M, Kim JH, et al. Mapping of machine learning approaches for description, prediction, and causal inference in the social and health sciences. *Sci Adv*. 2022;8(42):eabk1942. doi:[10.1126/sciadv.abk1942](https://doi.org/10.1126/sciadv.abk1942)
123. Bodnar LM, Cartus AR, Kirkpatrick SI, et al. Machine learning as a strategy to account for dietary synergy: an illustration based on dietary intake and adverse pregnancy outcomes. *Am J Clin Nutr*. 2020;111:1235-1243. doi:[10.1093/AJCN/NQAA027](https://doi.org/10.1093/AJCN/NQAA027)
124. Misawa D, Fukuyoshi J, Sengoku S. Cancer prevention using machine learning, nudge theory and social impact bond. *Int J Environ Res Public Health*. 2020;17:790. doi:[10.3390/IJERPH17030790](https://doi.org/10.3390/IJERPH17030790)
125. Torous J, Larsen ME, Depp C, et al. Smartphones, sensors, and machine learning to advance real-time prediction and interventions for suicide prevention: a review of current progress and next steps. *Curr Psychiatry Rep*. 2018;20:1-6. doi:[10.1007/S11920-018-0914-Y](https://doi.org/10.1007/S11920-018-0914-Y)
126. Delgadillo J, Gonzalez Salas Duhne P. Targeted prescription of cognitive-behavioral therapy versus person-centered counseling for depression using a machine learning approach. *J Consult Clin Psychol*. 2020;88:14-24. doi:[10.1037/CCP0000476](https://doi.org/10.1037/CCP0000476)
127. Hu L, Gu C. Estimation of causal effects of multiple treatments in healthcare database studies with rare outcomes. *Health Serv Outcomes Res Methodol*. 2021;21:287-308.
128. Mahase E. FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness. *BMJ*. 2021;373:n1462. doi:[10.1136/BMJ.N1462](https://doi.org/10.1136/BMJ.N1462)
129. Servick K. Alzheimer's drug approved despite murky results. *Science*. 2021;372:1141. doi:[10.1126/SCIENCE.372.6547.1141](https://doi.org/10.1126/SCIENCE.372.6547.1141)
130. Liu KY, Schneider LS, Howard R. The need to show minimum clinically important differences in Alzheimer's disease trials. *Lancet Psychiatry*. 2021;8:1013-1016. doi:[10.1016/S2215-0366\(21\)00197-8](https://doi.org/10.1016/S2215-0366(21)00197-8)
131. Mahase E. Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns. *BMJ*. 2023;380:p73. doi:[10.1136/BMJ.P73](https://doi.org/10.1136/BMJ.P73)
132. Lance. Lecanemab for Alzheimer's disease: tempering hype and hope. *Lancet*. 2022;400:1899. doi:[10.1016/S0140-6736\(22\)02480-1](https://doi.org/10.1016/S0140-6736(22)02480-1)
133. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. *Alzheimers Dement*. *TRCI*. 2023;9:e12385. doi:[10.1002/TRC2.12385](https://doi.org/10.1002/TRC2.12385)
134. Nelson ME, Jester DJ, Petkus AJ, Anel R. Cognitive reserve, Alzheimer's neuropathology, and risk of dementia: a systematic review and meta-analysis. *Neuropsychol Rev*. 2021;31:233-250. doi:[10.1007/S11065-021-09478-4](https://doi.org/10.1007/S11065-021-09478-4)
135. Shannon OM, Ranson JM, Gregory S, et al. Mediterranean diet adherence is associated with lower dementia risk, independent of genetic predisposition: findings from the UK Biobank prospective cohort study. *BMC Med*. 2023;21:81. doi:[10.1186/S12916-023-02772-3/FIGURES/3](https://doi.org/10.1186/S12916-023-02772-3/FIGURES/3)
136. Jurcau A. The role of natural antioxidants in the prevention of dementia-where do we stand and future perspectives. *Nutrients*. 2021;13:1-22. doi:[10.3390/NU13020282](https://doi.org/10.3390/NU13020282)
137. Griñán-Ferré C, Bellver-Sanchis A, Izquierdo V, et al. The pleiotropic neuroprotective effects of resveratrol in cognitive decline and Alzheimer's disease pathology: from antioxidant to epigenetic therapy. *Ageing Res Rev*. 2021;67:101271. doi:[10.1016/J.ARR.2021.101271](https://doi.org/10.1016/J.ARR.2021.101271)
138. Littlejohns TJ, Kos K, Henley WE, Kuźma E, Llewellyn DJ. Vitamin D and Dementia. *J Prev Alzheimers Dis*. 2016;3:43-52. doi:[10.14283/JPAD.2015.68](https://doi.org/10.14283/JPAD.2015.68)
139. Kuźma E, Soni M, Littlejohns TJ, et al. Vitamin D and memory decline: two population-based prospective studies. *J Alzheimers Dis*. 2016;50:1099-1108. doi:[10.3233/JAD-150811](https://doi.org/10.3233/JAD-150811)
140. Whitty E, Mansour H, Aguirre E, et al. Efficacy of lifestyle and psychosocial interventions in reducing cognitive decline in older people: systematic review. *Ageing Res Rev*. 2020;62:101113. doi:[10.1016/J.ARR.2020.101113](https://doi.org/10.1016/J.ARR.2020.101113)
141. Lissek V, Suchan B. Preventing dementia? Interventional approaches in mild cognitive impairment. *Neurosci Biobehav Rev*. 2021;122:143-164. doi:[10.1016/J.NEUBIOREV.2020.12.022](https://doi.org/10.1016/J.NEUBIOREV.2020.12.022)
142. Rosenberg A, Ngandu T, Rusanen M, et al. Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: the FIN-GER trial. *Alzheimers Dement*. 2018;14:263-270. doi:[10.1016/J.JALZ.2017.09.006](https://doi.org/10.1016/J.JALZ.2017.09.006)
143. Kivipelto M, Mangialasche F, Snyder HM, et al. World-Wide FIN-GER Network: a global approach to risk reduction and prevention of dementia. *Alzheimers Dement*. 2020;16:1078-1094. doi:[10.1002/ALZ.12123](https://doi.org/10.1002/ALZ.12123)
144. Clark LT, Watkins L, Piña IL, et al. Increasing diversity in clinical trials: overcoming critical barriers. *Curr Probl Cardiol*. 2019;44:148-172. doi:[10.1016/J.CPCARDIOL.2018.11.002](https://doi.org/10.1016/J.CPCARDIOL.2018.11.002)
145. Soofi H. Ethical aspects of facilitating the recruitment of people with dementia for clinical trials: a call for further debate. *Br J Clin Pharmacol*. 2022;88:22-26. doi:[10.1111/BCP.14968](https://doi.org/10.1111/BCP.14968)
146. Whiteley WN, Anand S, Bangdiwala SI, et al. Are large simple trials for dementia prevention possible? *Age Ageing*. 2020;49:154-160. doi:[10.1093/AGEING/AFZ152](https://doi.org/10.1093/AGEING/AFZ152)
147. Indorewalla KK, O'Connor MK, Budson AE, Guess DiTerlizzi C, Jackson J. Modifiable barriers for recruitment and retention of older adults participants from underrepresented minorities in Alzheimer's disease research. *J Alzheimers Dis*. 2021;80:927-940. doi:[10.3233/JAD-201081](https://doi.org/10.3233/JAD-201081)
148. Gilmore-Bykovskiy AL, Jin Y, Gleason C, et al. Recruitment and retention of underrepresented populations in Alzheimer's disease research: a systematic review. *Alzheimers Dement (N Y)*. 2019;5:751-770. doi:[10.1016/J.TRCI.2019.09.018](https://doi.org/10.1016/J.TRCI.2019.09.018)
149. Hawe P, Potvin L. What is population health intervention research? *Can J Public Health*. 2009;100:I8. doi:[10.1007/BF03405503](https://doi.org/10.1007/BF03405503)
150. Coley N, Andrieu S, Gardette V, et al. Dementia prevention: methodological explanations for inconsistent results. *Epidemiol Rev*. 2008;30:35-66. doi:[10.1093/EPIREV/MXN010](https://doi.org/10.1093/EPIREV/MXN010)
151. Power R, Prado-Cabrero A, Mulcahy R, Howard A, Nolan JM. The role of nutrition for the aging population: implications for cognition and Alzheimer's disease. *Annu Rev Food Sci Technol*. 2019;10:619-639. doi:[10.1146/ANNUREV-FOOD-030216-030125](https://doi.org/10.1146/ANNUREV-FOOD-030216-030125)
152. Burgos N, Colliot O. Machine learning for classification and prediction of brain diseases: recent advances and upcoming challenges. *Curr Opin Neurol*. 2020;33:439-450. doi:[10.1097/WCO.0000000000000838](https://doi.org/10.1097/WCO.0000000000000838)
153. Graham SA, Lee EE, Jeste DV, et al. Artificial intelligence approaches to predicting and detecting cognitive decline in older adults: a conceptual review. *Psychiatry Res*. 2020;284:112732. doi:[10.1016/J.PSYCHRES.2019.112732](https://doi.org/10.1016/J.PSYCHRES.2019.112732)
154. Clarke N, Foltz P, Garrard P. How to do things with (thousands of) words: computational approaches to discourse analysis in Alzheimer's disease. *Cortex*. 2020;129:446-463. doi:[10.1016/J.CORTECH.2020.05.001](https://doi.org/10.1016/J.CORTECH.2020.05.001)
155. Thabtah F, Peebles D, Retzler J, Hathurusingha C. Dementia medical screening using mobile applications: a systematic review with a new mapping model. *J Biomed Inform*. 2020;111:103573. doi:[10.1016/J.JBI.2020.103573](https://doi.org/10.1016/J.JBI.2020.103573)
156. Battista P, Salvatore C, Berlingeri M, Cerasa A, Castiglioni I. Artificial intelligence and neuropsychological measures: the case of Alzheimer's disease. *Neurosci Biobehav Rev*. 2020;114:211-228. doi:[10.1016/J.NEUBIOREV.2020.04.026](https://doi.org/10.1016/J.NEUBIOREV.2020.04.026)



157. Danso SO, Muniz-Terrera G, Luz S, Ritchie C, (GloDePP) on behalf of the GDPP. Application of big data and artificial intelligence technologies to dementia prevention research: an opportunity for low-and-middle-income countries. *J Glob Health*. 2019;9:20322. doi:[10.7189/JOGH.09.020322](https://doi.org/10.7189/JOGH.09.020322)
158. Koychev I, Lawson J, Chessell T, et al. Deep and Frequent Phenotyping study protocol: an observational study in prodromal Alzheimer's disease. *BMJ Open*. 2019;9:e024498. doi:[10.1136/BMJOPEN-2018-024498](https://doi.org/10.1136/BMJOPEN-2018-024498)
159. Chen PH, Lien CW, Wu WC, Lee LS, Shaw JS. Gait-based machine learning for classifying patients with different types of mild cognitive impairment. *J Med Syst*. 2020;44. doi:[10.1007/S10916-020-01578-7](https://doi.org/10.1007/S10916-020-01578-7)
160. Yamada Y, Shinkawa K, Kobayashi M, et al. Combining multimodal behavioral data of gait, speech, and drawing for classification of Alzheimer's disease and mild cognitive impairment. *J Alzheimers Dis*. 2021;84:315-327. doi:[10.3233/JAD-210684](https://doi.org/10.3233/JAD-210684)
161. Ballard C, Aarsland D, Cummings J, et al. Drug repositioning and repurposing for Alzheimer disease. *Nat Rev Neurol*. 2020;16:661-673. doi:[10.1038/S41582-020-0397-4](https://doi.org/10.1038/S41582-020-0397-4)
162. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. *Nat Rev Drug Discov*. 2018;18:41-58. doi:[10.1038/nrd.2018.168](https://doi.org/10.1038/nrd.2018.168)
163. Ding J, Davis-Plourde KL, Sedaghat S, et al. Antihypertensive medications and risk for incident dementia and Alzheimer's disease: a meta-analysis of individual participant data from prospective cohort studies. *Lancet Neurol*. 2020;19:61-70. doi:[10.1016/S1474-4422\(19\)30393-X](https://doi.org/10.1016/S1474-4422(19)30393-X)
164. Newby D, Prieto-Alhambra D, Duarte-Salles T, et al. Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database case-control study. *Alzheimers Res Ther*. 2020;12(1):38. doi:[10.1186/s13195-020-00606-5](https://doi.org/10.1186/s13195-020-00606-5)
165. Newby D, Linden AB, Fernandes M, et al. Comparative effect of metformin versus sulfonylureas with dementia and Parkinson's disease risk in US patients over 50 with type 2 diabetes mellitus. *BMJ Open Diabetes Res Care*. 2022;10:e003036. doi:[10.1136/BMJDR-2022-003036](https://doi.org/10.1136/BMJDR-2022-003036)
166. Yang F, Zhang Q, Ji X, et al. Machine learning applications in drug repurposing. *Interdiscip Sci*. 2022;1:1-7. doi:[10.1007/S12539-021-00487-8/TABLES/1](https://doi.org/10.1007/S12539-021-00487-8/TABLES/1)
167. Rodriguez S, Hug C, Todorov P, et al. Machine learning identifies candidates for drug repurposing in Alzheimer's disease. *Nat Commun*. 2021;12:1-13. doi:[10.1038/s41467-021-21330-0](https://doi.org/10.1038/s41467-021-21330-0)
168. Liu R, Wei L, Zhang P. A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. *Nat Mach Intell*. 2021;3:68-75. doi:[10.1038/s42256-020-00276-w](https://doi.org/10.1038/s42256-020-00276-w)
169. Xu J, Zhang P, Huang Y, et al. Multimodal single-cell/nucleus RNA sequencing data analysis uncovers molecular networks between disease-associated microglia and astrocytes with implications for drug repurposing in Alzheimer's disease. *Genome Res*. 2021;31:1900-1912. doi:[10.1101/GR.272484.120](https://doi.org/10.1101/GR.272484.120)
170. Fang J, Zhang P, Wang Q, et al. Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease. *Alzheimers Res Ther*. 2022;14:1-23. doi:[10.1186/S13195-021-00951-Z/METRICS](https://doi.org/10.1186/S13195-021-00951-Z/METRICS)
171. Tsuji S, Hase T, Yachie-Kinoshita A, et al. Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer's disease. *Alzheimer's Res Ther*. 2021;13:1-15. doi:[10.1186/S13195-021-00826-3](https://doi.org/10.1186/S13195-021-00826-3)
172. Tomlinson A, Furukawa TA, Efthimiou O, et al. Personalise antidepressant treatment for unipolar depression combining individual choices, risks and big data (PETRUSHKA): rationale and protocol. *Evid Based Ment Health*. 2020;23:52-56. doi:[10.1136/EBMENTAL-2019-300118](https://doi.org/10.1136/EBMENTAL-2019-300118)
173. Liu Q, Vaci N, Koychev I, et al. Personalised treatment for cognitive impairment in dementia: development and validation of an artificial intelligence model. *BMC Med*. 2022;20:1-12. doi:[10.1186/S12916-022-02250-2](https://doi.org/10.1186/S12916-022-02250-2)
174. Nasief H, Zheng C, Schott D, et al. A machine learning based delta-radiomics process for early prediction of treatment response of pancreatic cancer. *Npj Precision Oncol*. 2019;3:1-10. doi:[10.1038/s41698-019-0096-z](https://doi.org/10.1038/s41698-019-0096-z)
175. Shayesteh S, Nazari M, Salahshour A, et al. Treatment response prediction using MRI-based pre-, post-, and delta-radiomic features and machine learning algorithms in colorectal cancer. *Med Phys*. 2021;48:3691-3701. doi:[10.1002/MP.14896](https://doi.org/10.1002/MP.14896)
176. Abajian A, Murali N, Savic LJ, et al. Predicting treatment response to intra-arterial therapies for hepatocellular carcinoma with the use of supervised machine learning—an artificial intelligence concept. *J Vasc Interv Radiol*. 2018;29:850-857. doi:[10.1016/JJVIR.2018.01.769](https://doi.org/10.1016/JJVIR.2018.01.769). e1.
177. Croce P, Ricci L, Pulitano P, et al. Machine learning for predicting lev- etiracetam treatment response in temporal lobe epilepsy. *Clin Neurophysiol*. 2021;132:3035-3042. doi:[10.1016/J.CLINPH.2021.08.024](https://doi.org/10.1016/J.CLINPH.2021.08.024)
178. Ambrosen KS, Skjærbaek MW, Foldager J, et al. A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data. *Transl Psychiatry*. 2020;10:1-13. doi:[10.1038/s41398-020-00962-8](https://doi.org/10.1038/s41398-020-00962-8)
179. Mooney SJ, Keil AP, Westreich DJ. Thirteen questions about using machine learning in causal research (you won't believe the answer to number 10!). *Am J Epidemiol*. 2021;190:1476. doi:[10.1093/AJE/KWAB047](https://doi.org/10.1093/AJE/KWAB047)
180. Lecca P. Machine learning for causal inference in biological networks: perspectives of this challenge. *Front Bioinform*. 2021;1:746712. doi:[10.3389/FBINF.2021.746712](https://doi.org/10.3389/FBINF.2021.746712)
181. Besser LM, Brenowitz WD, Meyer OL, Hoermann S, Renne J. Methods to address self-selection and reverse causation in studies of neighborhood environments and brain health. *Int J Environ Res Public Health*. 2021;18:6484. doi:[10.3390/IJERPH18126484](https://doi.org/10.3390/IJERPH18126484)
182. Sanchez P, Voisey JP, Xia T, Watson HI, O'Neil AQ, Tsafaris SA. Causal machine learning for healthcare and precision medicine. *R Soc Open Sci*. 2022;9(8). doi:[10.1098/RSOS.220638](https://doi.org/10.1098/RSOS.220638)
183. Blakely T, Lynch J, Simons K, Bentley R, Rose S. Reflection on modern methods: when worlds collide—prediction, machine learning and causal inference. *Int J Epidemiol*. 2020;49:2058. doi:[10.1093/IJE/DYZ132](https://doi.org/10.1093/IJE/DYZ132)
184. Petersen ML, Van Der Laan MJ. Causal models and learning from data: integrating causal modeling and statistical estimation. *Epidemiology*. 2014;25:418. doi:[10.1097/EDE.0000000000000078](https://doi.org/10.1097/EDE.0000000000000078)
185. Prosperi M, Ghosh S, Chen Z, et al. Causal AI with Real World Data: do Statins Protect from Alzheimer's Disease Onset? ACM International Conference Proceeding Series. 2021:296-303. doi:[10.1145/3472813.3473206](https://doi.org/10.1145/3472813.3473206)
186. Richens JG, Lee CM, Johri S. Improving the accuracy of medical diagnosis with causal machine learning. *Nat Commun*. 2020;11:1-9. doi:[10.1038/s41467-020-17419-7](https://doi.org/10.1038/s41467-020-17419-7)
187. Jawadekar N, Kezios K, Odden MC, et al. Practical guide to honest causal forests for identifying heterogeneous treatment effects. *Am J Epidemiol*. 2023;192:1155-1165. doi:[10.1093/AJE/KWAD043](https://doi.org/10.1093/AJE/KWAD043)
188. Andrews RM, Shpitser I, Lopez O, et al. Examining the causal mediating role of brain pathology on the relationship between diabetes and cognitive impairment: the Cardiovascular Health Study. *J R Stat Soc Ser A Stat Soc*. 2020;183:1705. doi:[10.1111/RSSA.12570](https://doi.org/10.1111/RSSA.12570)
189. Kimura D, Nakatani K, Takeda T, et al. Analysis of causal relationships by structural equation modeling to determine the factors

- influencing cognitive function in elderly people in Japan. *PLoS One*. 2015;10:e0117554. doi:[10.1371/JOURNAL.PONE.0117554](https://doi.org/10.1371/JOURNAL.PONE.0117554)
190. Yoon CH, Torrance R, Scheinerman N. Machine learning in medicine: should the pursuit of enhanced interpretability be abandoned? *J Med Ethics*. 2022;48:581-585. doi:[10.1136/MEDETHICS-2020-107102](https://doi.org/10.1136/MEDETHICS-2020-107102)
  191. Kolyshkina I, Simoff S. Interpretability of machine learning solutions in public healthcare: the CRISP-ML approach. *Front Big Data*. 2021;4:18. doi:[10.3389/FDATA.2021.660206/BIBTEX](https://doi.org/10.3389/FDATA.2021.660206/BIBTEX)
  192. Meng C, Trinh L, Xu N, Enouen J, Liu Y. Interpretability and fairness evaluation of deep learning models on MIMIC-IV dataset. *Sci Reports*. 2022;12:1-28. doi:[10.1038/s41598-022-11012-2](https://doi.org/10.1038/s41598-022-11012-2)
  193. Saint Y, Aquino J, Carter SM, et al. Practical, epistemic and normative implications of algorithmic bias in healthcare artificial intelligence: a qualitative study of multidisciplinary expert perspectives. *J Med Ethics*. 2023. doi:[10.1136/JME-2022-108850](https://doi.org/10.1136/JME-2022-108850)
  194. Mukadam N, Marston L, Lewis G, Mathur R, Rait G, Livingston G. Incidence, age at diagnosis and survival with dementia across ethnic groups in England: a longitudinal study using electronic health records. *Alzheimer Dement*. 2023;19:1300-1307. doi:[10.1002/ALZ.12774](https://doi.org/10.1002/ALZ.12774)
  195. Shiekh SI, Cadogan SL, Lin LY, Mathur R, Smeeth L, Warren-Gash C. Ethnic differences in dementia risk: a systematic review and meta-analysis. *J Alzheimers Dis*. 2021;80:337-355. doi:[10.3233/JAD-201209](https://doi.org/10.3233/JAD-201209)
  196. Sahin D, Jessen F, Kambeitz J. Algorithmic fairness in biomarker-based machine learning models to predict Alzheimer's dementia in individuals with mild cognitive impairment. *Alzheimer Dement*. 2022;18:e062125. doi:[10.1002/ALZ.062125](https://doi.org/10.1002/ALZ.062125)
  197. Wang R, Chaudhari P, Davatzikos C. Brief Report: bias in machine learning models can be significantly mitigated by careful training: evidence from neuroimaging studies. *Proc Natl Acad Sci U S A*. 2023;120:2211613120. doi:[10.1073/PNAS.2211613120](https://doi.org/10.1073/PNAS.2211613120)
  198. Nichols JA, Herbert Chan HW, Baker MAB. Machine learning: applications of artificial intelligence to imaging and diagnosis. *Biophys Rev*. 2019;11:111-118. doi:[10.1007/S12551-018-0449-9/FIGURES/4](https://doi.org/10.1007/S12551-018-0449-9/FIGURES/4)
  199. Mutasa S, Sun S, Ha R. Understanding artificial intelligence based radiology studies: what is overfitting? *Clin Imaging*. 2020;65:96. doi:[10.1016/J.CLINIMAG.2020.04.025](https://doi.org/10.1016/J.CLINIMAG.2020.04.025)
  200. Padmanabhan S, Tran TQB, Dominiczak AF. Artificial intelligence in hypertension. *Circ Res*. 2021;128:1100-1118. doi:[10.1161/CIRCRESAHA.121.318106](https://doi.org/10.1161/CIRCRESAHA.121.318106)
  201. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. *BMC Med*. 2019;17:1-9. doi:[10.1186/S12916-019-1426-2/PEER-REVIEW](https://doi.org/10.1186/S12916-019-1426-2/PEER-REVIEW)
  202. Pellegrini E, Ballerini L, del Hernandez MCV, et al. Machine learning of neuroimaging for assisted diagnosis of cognitive impairment and dementia: a systematic review. *Alzheimers Dement (Amst)*. 2018;10:519-535. doi:[10.1016/J.DADM.2018.07.004](https://doi.org/10.1016/J.DADM.2018.07.004)
  203. Joyce DW, Kormilitzin A, Smith KA, Cipriani A. Explainable artificial intelligence for mental health through transparency and interpretability for understandability. *Npj Digital Medicine*. 2023;6:1-7. doi:[10.1038/s41746-023-00751-9](https://doi.org/10.1038/s41746-023-00751-9)
  204. Lipovetsky S, Conklin M. Analysis of regression in game theory approach. *Appl Stoch Models Bus Ind*. 2001;17:319-330. doi:[10.1002/ASMB.446](https://doi.org/10.1002/ASMB.446)
  205. Ribeiro MT, Singh S, Guestrin C. "Why Should I Trust You?": Explaining the predictions of any classifier. NAACL-HLT 2016 - 2016 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Proceedings of the Demonstrations Session 2016:97-101. doi:[10.18653/v1/n16-3020](https://doi.org/10.18653/v1/n16-3020)
  206. Sarica A, Quattrone A, Quattrone A. Explainable boosting machine for predicting Alzheimer's disease from MRI Hippocampal Subfields. In: Mahmud M, Kaiser MS, Vassanelli S, Dai Q, Zhong N, (eds). *Brain Informatics. BI 2021. Lecture Notes in Computer Science* (Vol. 12960). Springer, Cham; 2021. doi:[10.1007/978-3-030-86993-9\\_31](https://doi.org/10.1007/978-3-030-86993-9_31)

## SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Newby D, Orgeta V, Marshall CR, et al. Artificial intelligence for dementia prevention. *Alzheimer's Dement*. 2023;19:5952-5969.  
<https://doi.org/10.1002/alz.13463>